{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:09:13Z","timestamp":1788480553401,"version":"build-2803163510"},"update-to":[{"DOI":"10.1002\/14651858.cd012721.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T00:00:00Z","timestamp":1621641600000}}],"reference-count":642,"publisher":"Wiley","issue":"5","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012721.pub3","type":"journal-article","created":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T13:29:18Z","timestamp":1621690158000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction"],"prefix":"10.1002","volume":"2021","author":[{"given":"Nicole","family":"Martin","sequence":"additional","affiliation":[{"name":"Institute of Health Informatics Research; University College London; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthick","family":"Manoharan","sequence":"additional","affiliation":[{"name":"Emergency Department; John Radcliffe Hospital; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ceri","family":"Davies","sequence":"additional","affiliation":[{"name":"Department of Cardiology; Barts Heart Centre, St Bartholomew's Hospital; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R Thomas","family":"Lumbers","sequence":"additional","affiliation":[{"name":"Institute of Health Informatics; University College London; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,5,22]]},"reference":[{"key":"10.1002\/14651858.CD012721.pub3-BIB0001|cit1","first-page":"850","article-title":"Independent and additive influence of statin and beta-blocker on long-term prognosis in patients with chronic heart failure and preserved systolic function","volume":"31","author":"Adamyan","year":"2010","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0002|cit2","first-page":"S23","article-title":"Influence of statin and beta-blocker on long-term prognosis in patients with chronic heart failure and preserved systolic function","volume":"9","author":"Tumasyan","year":"2010","journal-title":"European Journal of Heart Failure Supplements"},{"issue":"5","key":"10.1002\/14651858.CD012721.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nrcardio.2013.51","article-title":"Heart failure: Aldosterone antagonism for HFpEF","volume":"10","author":"Borlaug","year":"2013","journal-title":"Nature Reviews Cardiology"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0004|cit4","first-page":"155","article-title":"Economic impact of heart failure with preserved ejection fraction: Insights from the prospective, randomized placebo-controlled ALDO-DHF trial","volume":"19","author":"Djawid Hashemi","year":"2017","journal-title":"European Journal of Heart Failure"},{"issue":"2","key":"10.1002\/14651858.CD012721.pub3-BIB0005|cit5","first-page":"104","article-title":"Galectin-3 in heart failure with preserved ejection fraction-the effects of chronic aldosterone receptor blockade (the ALDO-DHF trial)","volume":"54","author":"Durstewitz","year":"2013","journal-title":"Internist"},{"issue":"6","key":"10.1002\/14651858.CD012721.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ijcard.2013.10.018","article-title":"Differential interaction of clinical characteristics with key functional parameters in heart failure with preserved ejection fraction--results of the Aldo-DHF trial","volume":"169","author":"Edelmann","year":"2013","journal-title":"International Journal of Cardiology"},{"issue":"2","key":"10.1002\/14651858.CD012721.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/ejhf.203","article-title":"Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial","volume":"17","author":"Edelmann","year":"2015","journal-title":"European Journal of Heart Failure"},{"issue":"8","key":"10.1002\/14651858.CD012721.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/eurjhf\/hfq087","article-title":"Rationale and design of the 'aldosterone receptor blockade in diastolic heart failure' trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF)","volume":"12","author":"Edelmann","year":"2010","journal-title":"European Journal of Heart Failure"},{"issue":"2","key":"10.1002\/14651858.CD012721.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1001\/jama.2013.7976","article-title":"Aldosterone inhibition in patients with heart failure with preserved ejection fraction--reply","volume":"310","author":"Edelmann","year":"2013","journal-title":"JAMA"},{"issue":"8","key":"10.1002\/14651858.CD012721.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jama.2013.905","article-title":"Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial","volume":"309","author":"Edelmann","year":"2013","journal-title":"JAMA"},{"issue":"2012","key":"10.1002\/14651858.CD012721.pub3-BIB0011|cit11","first-page":"12","article-title":"ALDO-DHF & Paramount","volume":"2","author":"Elguindy","year":"2013","journal-title":"Global Cardiology Science & Practice"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0012|cit12","unstructured":"Aldosterone receptor blockade in diastolic heart failure. A double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure www.clinicaltrialsregister.eu\/ctr-search\/trial\/2006-002605-31\/DE"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0013|cit13","unstructured":"Aldosterone receptor blockade in diastolic heart failure: a double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure www.isrctn.com\/ISRCTN94726526"},{"issue":"2","key":"10.1002\/14651858.CD012721.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1001\/jama.2013.7967","article-title":"Aldosterone inhibition in patients with heart failure with preserved ejection fraction","volume":"10","author":"Lund","year":"2013","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0015|cit15","first-page":"130","article-title":"Gender specific treatment effects of spironolactone in diastolic heart failure: Insight from ALDO-DHF","volume":"18","author":"Trippel","year":"2016","journal-title":"European Journal of Heart Failure"},{"issue":"9","key":"10.1002\/14651858.CD012721.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2459\/JCM.0b013e3281053a9a","article-title":"Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure)","volume":"8","author":"Boccanelli","year":"2007","journal-title":"Journal of Cardiovascular Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012721.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/eurjhf\/hfn015","article-title":"Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results","volume":"11","author":"Boccanelli","year":"2009","journal-title":"European Journal of Heart Failure"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012721.pub3-BIB0018|cit18","first-page":"66S","article-title":"The AREA IN-CHF trial (antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure): rationale and design","volume":"6","author":"Cacciatore","year":"2005","journal-title":"Italian Heart Journal"},{"issue":"10","key":"10.1002\/14651858.CD012721.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.numecd.2010.02.012","article-title":"Effect of canrenone on left ventricular mechanics in patients with mild systolic heart failure and metabolic syndrome: the AREA-in-CHF study","volume":"21","author":"De Simone","year":"2011","journal-title":"Nutrition, Metabolism and Cardiovascular Diseases"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0020|cit20","unstructured":"Antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure. AREA IN-CHF study clinicaltrials.gov\/ct2\/show\/NCT00403910"},{"issue":"7","key":"10.1002\/14651858.CD012721.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/0002-9149(93)90520-M","article-title":"Effect of enalapril on congestive heart failure treated with diuretics in elderly patients with prior myocardial infarction and normal left ventricular ejection fraction","volume":"71","author":"Aronow","year":"1993","journal-title":"American Journal of Cardiology"},{"issue":"2","key":"10.1002\/14651858.CD012721.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0002-9149(97)00320-2","article-title":"Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction > or = 40% treated with diuretics plus angiotensin-converting enzyme inhibitors","volume":"80","author":"Aronow","year":"1997","journal-title":"American Journal of Cardiology"},{"issue":"11","key":"10.1002\/14651858.CD012721.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/S0002-9149(98)00174-X","article-title":"Effect of benazepril on complex ventricular arrhythmias in older patients with congestive heart failure, prior myocardial infarction, and normal left ventricular ejection fraction","volume":"81","author":"Aronow","year":"1998","journal-title":"American Journal of Cardiology"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0024|cit24","unstructured":"Effects of Candesartan Cilexetil vs standard therapy on serum levels of brain natriuretic peptide in patients suffering from chronic heart failure with depressed and preserved systolic function www.clinicaltrialsregister.eu\/ctr-search\/trial\/2005-001306-87\/IT"},{"issue":"6","key":"10.1002\/14651858.CD012721.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s10557-012-6370-8","article-title":"Effects of candesartan on left ventricular function, aldosterone and BNP in chronic heart failure","volume":"26","author":"Aleksova","year":"2012","journal-title":"Cardiovascular Drugs and Therapy"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0026|cit26","unstructured":"Efficacy of candesartan on brain natriuretic peptide levels in subjects with chronic heart failure (CANDHEART) clinicaltrials.gov\/ct2\/show\/NCT00843154"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0027|cit27","unstructured":"Candesartan \u201cadded\u201d therapy for treatment optimization of symptomatic heart failure with diastolic dysfunction in diabetic and hypertensive patients. A randomized, placebo-controlled, double-blind, parallel-group and multicentre clinical phase III study investigating the effects on NT-proBNP over 6 months. www.clinicaltrialsregister.eu\/ctr-search\/trial\/2007-003070-26\/DE"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0028|cit28","unstructured":"Efficacy of candesartan on symptomatic heart failure in treating diabetic and hypertensive patients clinicaltrials.gov\/ct2\/show\/NCT00775840"},{"issue":"2","key":"10.1002\/14651858.CD012721.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/ejhf.221","article-title":"Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme","volume":"17","author":"Badar","year":"2015","journal-title":"European Journal of Heart Failure"},{"issue":"4","key":"10.1002\/14651858.CD012721.pub3-BIB0030|cit30","first-page":"590","article-title":"Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction","volume":"7","author":"Bello","year":"2014","journal-title":"Circulation"},{"issue":"20","key":"10.1002\/14651858.CD012721.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.jacc.2011.12.044","article-title":"Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program","volume":"59","author":"Castagno","year":"2012","journal-title":"Journal of the American College of Cardiology"},{"issue":"Suppl 21","key":"10.1002\/14651858.CD012721.pub3-BIB0032|cit32","first-page":"A17352","article-title":"Incidence and predictors of stroke in patients with chronic heart failure: Does left ventricular function Matter? Insights From the CHARM Program","volume":"124","author":"Castagno","year":"2011","journal-title":"Circulation"},{"issue":"7","key":"10.1002\/14651858.CD012721.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/eurjhf\/hfq065","article-title":"Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme","volume":"12","author":"Chang","year":"2010","journal-title":"European Journal of Heart Failure"},{"issue":"24","key":"10.1002\/14651858.CD012721.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1093\/eurheartj\/ehn476","article-title":"Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme","volume":"29","author":"Cohen-Solal","year":"2008","journal-title":"European Heart Journal"},{"issue":"1","key":"10.1002\/14651858.CD012721.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2147\/vhrm.2008.04.01.223","article-title":"Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) and resource utilization and costs in Italy","volume":"4","author":"Colombo","year":"2008","journal-title":"Vascular Health and Risk Management"},{"issue":"12","key":"10.1002\/14651858.CD012721.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1002\/ejhf.609","article-title":"Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme","volume":"18","author":"Damman","year":"2016","journal-title":"European Journal of Heart Failure"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0037|cit37","first-page":"284","article-title":"Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction","volume":"34","author":"Desai","year":"2013","journal-title":"European Journal of Heart Failure"},{"issue":"6","key":"10.1002\/14651858.CD012721.pub3-BIB0038|cit38","first-page":"895","article-title":"Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction","volume":"7","author":"Desai","year":"2014","journal-title":"Circulation"},{"issue":"5","key":"10.1002\/14651858.CD012721.pub3-BIB0039|cit39","first-page":"280","article-title":"Angiotensin II receptor antagonists in the treatment of heart failure: Background to and design of the CHARM study","volume":"9","author":"Dubrey","year":"2002","journal-title":"British Journal of Cardiology"},{"issue":"7","key":"10.1002\/14651858.CD012721.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"A379","DOI":"10.1016\/j.jval.2011.08.804","article-title":"Resource utilization and costs for candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) programme for the Austrian setting","volume":"14","author":"Fruhwald","year":"2011","journal-title":"Value in Health"},{"issue":"15","key":"10.1002\/14651858.CD012721.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1001\/archinte.168.15.1699","article-title":"The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program","volume":"168","author":"Gerstein","year":"2008","journal-title":"Archives of Internal Medicine"},{"issue":"6","key":"10.1002\/14651858.CD012721.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.amjcard.2008.04.048","article-title":"Usefulness of N-terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction","volume":"102","author":"McKelvie","year":"2008","journal-title":"American Journal of Cardiology"},{"issue":"8","key":"10.1002\/14651858.CD012721.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/j.cardfail.2012.06.490","article-title":"Prognostic impact of an ischemic etiology of chronic heart failure across the spectrum of ejection fractions in the charm program","volume":"18","author":"Gupta","year":"2012","journal-title":"Journal of Cardiac Failure"},{"issue":"5","key":"10.1002\/14651858.CD012721.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ejheart.2006.11.006","article-title":"Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme","volume":"9","author":"Hawkins","year":"2007","journal-title":"European Journal of Heart Failure"},{"issue":"1","key":"10.1002\/14651858.CD012721.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1136\/hrt.2005.083949","article-title":"Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme","volume":"93","author":"Hawkins","year":"2007","journal-title":"Heart"},{"issue":"6","key":"10.1002\/14651858.CD012721.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/eurjhf\/hfq040","article-title":"Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme","volume":"12","author":"Hawkins","year":"2010","journal-title":"European Journal of Heart Failure"},{"issue":"9689","key":"10.1002\/14651858.CD012721.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0140-6736(09)61378-7","article-title":"Albuminuria in chronic heart failure: prevalence and prognostic importance","volume":"374","author":"Jackson","year":"2009","journal-title":"Lancet"},{"issue":"9","key":"10.1002\/14651858.CD012721.pub3-BIB0048|cit48","first-page":"1063","article-title":"Angiotensin receptor blockers in heart failure. CHARM Study","volume":"45","author":"Kochsiek","year":"2004","journal-title":"Internist"},{"issue":"1","key":"10.1002\/14651858.CD012721.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1161\/CIRCULATIONAHA.114.012284","article-title":"International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction","volume":"131","author":"Kristensen","year":"2015","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/ejhf.1149","article-title":"Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum","volume":"20","author":"Lund","year":"2018","journal-title":"European Journal of Heart Failure"},{"issue":"11","key":"10.1002\/14651858.CD012721.pub3-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1093\/eurheartj\/ehn153","article-title":"Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme","volume":"29","author":"MacDonald","year":"2008","journal-title":"European Heart Journal"},{"issue":"1","key":"10.1002\/14651858.CD012721.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1586\/14779072.7.1.9","article-title":"The CHARM program: the effects of candesartan for the management of patients with chronic heart failure","volume":"7","author":"McKelvie","year":"2009","journal-title":"Expert Review Cardiovascular Therapy"},{"issue":"3","key":"10.1002\/14651858.CD012721.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S1388-9842(03)00052-7","article-title":"Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme","volume":"5","author":"McMurray","year":"2003","journal-title":"European Journal of Heart Failure"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012721.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.3317\/JRAAS.2004.019","article-title":"Angiotensin inhibition in heart failure","volume":"5","author":"McMurray","year":"2004","journal-title":"Journal of the Renin Angiotensin Aldosterone System"},{"issue":"24","key":"10.1002\/14651858.CD012721.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1016\/j.jacc.2008.09.011","article-title":"Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program","volume":"52","author":"Meredith","year":"2008","journal-title":"Journal of the American College of Cardiology"},{"issue":"3","key":"10.1002\/14651858.CD012721.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11886-004-0023-x","article-title":"The candesartan in heart failure-assessment of reduction in mortality and morbidity-preserved trial","volume":"6","author":"Meyer","year":"2004","journal-title":"Current Cardiology Reports"},{"issue":"2","key":"10.1002\/14651858.CD012721.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ejheart.2005.07.006","article-title":"Pulsatile hemodynamic effects of candesartan in patients with chronic heart failure: the CHARM Program","volume":"8","author":"Mitchell","year":"2006","journal-title":"European Journal of Heart Failure"},{"issue":"7","key":"10.1002\/14651858.CD012721.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1161\/CIRCULATIONAHA.105.582577","article-title":"Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program","volume":"113","author":"O'Meara","year":"2006","journal-title":"Circulation"},{"issue":"24","key":"10.1002\/14651858.CD012721.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1161\/CIRCULATIONAHA.106.673442","article-title":"Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program","volume":"115","author":"O'Meara","year":"2007","journal-title":"Circulation"},{"issue":"10","key":"10.1002\/14651858.CD012721.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1016\/j.jacc.2006.01.060","article-title":"Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program","volume":"47","author":"Olsson","year":"2006","journal-title":"Journal of the American College of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD012721.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/01.hjh.0000220400.08128.fa","article-title":"Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme","volume":"24","author":"Ostergren","year":"2006","journal-title":"Journal of Hypertension. Supplements"},{"issue":"6","key":"10.1002\/14651858.CD012721.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.jacc.2006.08.062","article-title":"Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from the CHARM Echocardiographic Substudy-CHARMES","volume":"49","author":"Persson","year":"2007","journal-title":"Journal of the American College of Cardiology"},{"issue":"21","key":"10.1002\/14651858.CD012721.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1093\/eurheartj\/ehn420","article-title":"Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme","volume":"29","author":"Pocock","year":"2008","journal-title":"European Heart Journal"},{"issue":"1","key":"10.1002\/14651858.CD012721.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.hfc.2004.10.003","article-title":"Role of neurohormonal modulators in heart failure with relatively preserved systolic function","volume":"1","author":"Rapp","year":"2005","journal-title":"Heart Failure Clinic"},{"issue":"3","key":"10.1002\/14651858.CD012721.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1527-5299.2004.02806.x","article-title":"ACE inhibitor intolerance and lessons learned from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) trials","volume":"10","author":"Sica","year":"2004","journal-title":"Congestive Heart Failure"},{"issue":"24","key":"10.1002\/14651858.CD012721.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1161\/CIRCULATIONAHA.105.561423","article-title":"Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients","volume":"112","author":"Solomon","year":"2005","journal-title":"Circulationi"},{"issue":"13","key":"10.1002\/14651858.CD012721.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1161\/CIRCULATIONAHA.107.696906","article-title":"Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure","volume":"116","author":"Solomon","year":"2007","journal-title":"Circulation"},{"issue":"15","key":"10.1002\/14651858.CD012721.pub3-BIB0068|cit68","first-page":"2180","article-title":"Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program.[Erratum appears in Circulation. 2005 Jan 25;111(3):378]","volume":"110","author":"Somon","year":"2004","journal-title":"Circulation"},{"issue":"3","key":"10.1002\/14651858.CD012721.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S1071-9164(99)90013-1","article-title":"Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity (CHARM): Rationale and design","volume":"5","author":"Swedberg","year":"1999","journal-title":"Journal of Cardiac Failure"},{"issue":"10","key":"10.1002\/14651858.CD012721.pub3-BIB0070|cit70","first-page":"453","article-title":"Congress of the European Society of Cardiology 2003 in Vienna. Convincing results of candesartan in heart failure","volume":"10","author":"Woisetschlager","year":"2003","journal-title":"Journal fur Kardiologie"},{"issue":"9386","key":"10.1002\/14651858.CD012721.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0072|cit72","unstructured":"Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity and left ventricular function of the patients with diastolic dysfunction (ELANDD) www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2004-000746-20"},{"issue":"2","key":"10.1002\/14651858.CD012721.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/eurjhf\/hfr161","article-title":"Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study","volume":"14","author":"Conraads","year":"2012","journal-title":"European Journal of Heart Failure"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00392-009-0098-x","article-title":"Effect of the long-term administration of nebivolol on clinical symptoms, exercise capacity and left ventricular function in patients with heart failure and preserved left ventricular ejection fraction: background, aims and design of the ELANDD study","volume":"99","author":"Kamp","year":"2010","journal-title":"Clinical Research in Cardiology"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0075|cit75","unstructured":"Treatment of diastolic heart failure: the role of blockade of the renin-angiotensin system. A comparison of diuretics with an angiotensin converting enzyme inhibitor, angiotensin receptor blockade or diuretics alone www2.ccrb.cuhk.edu.hk\/registry\/public\/15"},{"issue":"5","key":"10.1002\/14651858.CD012721.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1136\/hrt.2007.117978","article-title":"The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction","volume":"94","author":"Yip","year":"2008","journal-title":"Heart"},{"issue":"11","key":"10.1002\/14651858.CD012721.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/ejhf.172","article-title":"A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction","volume":"16","author":"Adabag","year":"2014","journal-title":"European Journal of Heart Failure"},{"issue":"5","key":"10.1002\/14651858.CD012721.pub3-BIB0078|cit78","first-page":"569","article-title":"Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial","volume":"4","author":"Anand","year":"2011","journal-title":"Circulation"},{"issue":"6","key":"10.1002\/14651858.CD012721.pub3-BIB0079|cit79","first-page":"337","article-title":"Heart failure patients with preserved left ventricular ejection fraction did not benefit from additional ARB therapy","volume":"19","year":"2008","journal-title":"Cardiovascular Journal of Africa"},{"issue":"4","key":"10.1002\/14651858.CD012721.pub3-BIB0080|cit80","first-page":"717","article-title":"Clinical characteristics and outcomes of patients with coronary artery disease and angina: analysis of the irbesartan in patients with heart failure and preserved systolic function trial","volume":"8","author":"Badar","year":"2015","journal-title":"Circulation"},{"issue":"6","key":"10.1002\/14651858.CD012721.pub3-BIB0081|cit81","article-title":"ARBs and the impact of worsening renal function in heart failure patients with preserved EF","volume":"30","author":"Blandon","year":"2014","journal-title":"Cardiology Review"},{"issue":"7","key":"10.1002\/14651858.CD012721.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/ejhf.85","article-title":"Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve)","volume":"16","author":"Bohm","year":"2014","journal-title":"European Journal of Heart Failure"},{"issue":"8","key":"10.1002\/14651858.CD012721.pub3-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/ejhf.547","article-title":"Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial","volume":"18","author":"Cannon","year":"2016","journal-title":"European Journal of Heart Failure"},{"issue":"Suppl 22","key":"10.1002\/14651858.CD012721.pub3-BIB0084|cit84","first-page":"A15844","article-title":"Why are patients with heart failure and preserved ejection fraction hospitalized? Data from i-preserve","volume":"128","author":"Carson","year":"2013","journal-title":"Circulation"},{"issue":"8","key":"10.1002\/14651858.CD012721.pub3-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.cardfail.2005.06.432","article-title":"The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design","volume":"11","author":"Carson","year":"2005","journal-title":"Journal of Cardiac Failure"},{"issue":"10","key":"10.1002\/14651858.CD012721.pub3-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"A141.E1321","DOI":"10.1016\/S0735-1097(10)61322-8","article-title":"Heart failure with preserved ejection fraction: Mortality risk post first hospitalization - Data from I-preserve","volume":"55","author":"Carson","year":"2010","journal-title":"Journal of the American College of Cardiology"},{"issue":"10","key":"10.1002\/14651858.CD012721.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"A969","DOI":"10.1016\/S0735-1097(15)60969-X","article-title":"Markers of extracellular matrix turnover and risk of death in patients with heart failure with preserved ejection fraction: Results from I-PRESERVE","volume":"65","author":"Chow","year":"2015","journal-title":"Journal of the American College of Cardiology"},{"issue":"11","key":"10.1002\/14651858.CD012721.pub3-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.jacc.2014.01.087","article-title":"Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment","volume":"64","author":"Damman","year":"2014","journal-title":"Journal of the American College of Cardiology"},{"issue":"10","key":"10.1002\/14651858.CD012721.pub3-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"JC5","DOI":"10.7326\/0003-4819-150-10-200905190-02010","article-title":"ACP Journal Club. Irbesartan did not reduce all-cause death or CV hospitalization in heart failure and preserved ejection fraction","volume":"150","author":"Ezekowitz","year":"2009","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012721.pub3-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.cardfail.2016.06.006","article-title":"Prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction","volume":"23","author":"Gandhi","year":"2017","journal-title":"Journal of Cardiac Failure"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD012721.pub3-BIB0091|cit91","first-page":"A14299","article-title":"The prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction: Results from irbesartan in heart failure and preserved ejection fraction (I-preserve) trial","volume":"132","author":"Gandhi","year":"2015","journal-title":"Circulation"},{"issue":"3","key":"10.1002\/14651858.CD012721.pub3-BIB0092|cit92","first-page":"324","article-title":"Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial","volume":"4","author":"Haass","year":"2011","journal-title":"Circulationi"},{"issue":"9","key":"10.1002\/14651858.CD012721.pub3-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/ejhf.327","article-title":"Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response","volume":"17","author":"Kao","year":"2015","journal-title":"European Journal of Heart Failure"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0094|cit94","first-page":"S4","article-title":"Characterization of heart failure patients with preserved ejection fraction in the I-PRESERVE trial who have improved outcomes with irbesartan therapy","volume":"11","author":"Kao","year":"2012","journal-title":"European Journal of Heart Failure. Supplements"},{"issue":"1","key":"10.1002\/14651858.CD012721.pub3-BIB0095|cit95","first-page":"27","article-title":"Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE)","volume":"4","author":"Komajda","year":"2011","journal-title":"Circulation"},{"issue":"6","key":"10.1002\/14651858.CD012721.pub3-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jchf.2015.01.014","article-title":"Relative importance of history of heart failure hospitalization and N-Terminal pro-b-type Natriuretic Peptide level as predictors of outcomes in patients with heart failure and preserved ejection fraction","volume":"3","author":"Kristensen","year":"2015","journal-title":"JACC Heart Failure"},{"issue":"2","key":"10.1002\/14651858.CD012721.pub3-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/ejhf.211","article-title":"Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction","volume":"17","author":"Kristensen","year":"2015","journal-title":"European Journal of Heart Failure"},{"issue":"1","key":"10.1002\/14651858.CD012721.pub3-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1161\/CIRCULATIONAHA.114.012284","article-title":"International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction","volume":"131","author":"Kristensen","year":"2015","journal-title":"Circulation"},{"issue":"8","key":"10.1002\/14651858.CD012721.pub3-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1161\/CIRCULATIONAHA.116.024593","article-title":"Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction: A report from the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction)","volume":"135","author":"Kristensen","year":"2017","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/j.hlc.2010.06.849","article-title":"Peripheral collagen markers predict all-cause mortality and cardiovascular hospitalisation in patients with heart failure and preserved ejection fraction: Results of the I-PRESERVE collagen sub-study","volume":"19","author":"Krum","year":"2010","journal-title":"Heart, Lung and Circulation"},{"issue":"5","key":"10.1002\/14651858.CD012721.pub3-BIB0101|cit101","first-page":"561","article-title":"Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy","volume":"4","author":"Krum","year":"2011","journal-title":"Circulation"},{"issue":"5","key":"10.1002\/14651858.CD012721.pub3-BIB0102|cit102","first-page":"571","article-title":"Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failurewith Preserved Ejection Fraction (I-PRESERVE) trial","volume":"5","author":"Lam","year":"2012","journal-title":"Circulation"},{"issue":"23","key":"10.1002\/14651858.CD012721.pub3-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction","volume":"359","author":"Massie","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD012721.pub3-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.cardfail.2009.09.007","article-title":"Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial","volume":"16","author":"McKelvie","year":"2010","journal-title":"Journal of Cardiac Failure"},{"issue":"2","key":"10.1002\/14651858.CD012721.pub3-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ejheart.2007.12.010","article-title":"Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial","volume":"10","author":"McMurray","year":"2008","journal-title":"European Journal of Heart Failure"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0106|cit106","unstructured":"Irbesartan in heart failure with preserved systolic function (I-Preserve) clinicaltrials.gov\/show\/NCT00095238"},{"issue":"22","key":"10.1002\/14651858.CD012721.pub3-BIB0107|cit107","first-page":"A15893","article-title":"Risk of clinical outcomes and baseline atrial fibrillation: Irbesartan in heart failure with preserved ejection fraction (I-PRESERVE) trial","volume":"128","author":"Oluleye","year":"2013","journal-title":"Circulation"},{"issue":"6","key":"10.1002\/14651858.CD012721.pub3-BIB0108|cit108","first-page":"960","article-title":"History of atrial fibrillation as a risk factor in patients with heart failure and preserved ejection fraction","volume":"7","author":"Oluleye","year":"2014","journal-title":"Circulationi"},{"issue":"2","key":"10.1002\/14651858.CD012721.pub3-BIB0109|cit109","first-page":"217","article-title":"Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial","volume":"5","author":"Rector","year":"2012","journal-title":"Circulation"},{"issue":"12","key":"10.1002\/14651858.CD012721.pub3-BIB0110|cit110","first-page":"1258; author re","article-title":"Irbesartan for heart failure with preserved ejection fraction","volume":"360","author":"Schillaci","year":"2009","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0111|cit111","first-page":"S337","article-title":"I-preserve sub-study: Plasma collagen markers in the prediction of death and hospitalisation in patients with heart failure and preserved ejection fraction","volume":"49","author":"Schneider","year":"2011","journal-title":"Clinical Chemistry and Laboratory Medicine"},{"issue":"10","key":"10.1002\/14651858.CD012721.pub3-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"A38.E368","DOI":"10.1016\/S0735-1097(10)60369-5","article-title":"Acute coronary syndromes in patients with heart failure with preserved ejection fraction: A harbinger of death?","volume":"55","author":"Teerlink","year":"2010","journal-title":"JACC"},{"issue":"10","key":"10.1002\/14651858.CD012721.pub3-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"E706","DOI":"10.1016\/S0735-1097(13)60706-8","article-title":"Morbidity and mortality in diabetics with heart failure and a preserved ejection fraction: Results from the i-preserve trial","volume":"61","author":"Win","year":"2013","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0114|cit114","first-page":"867","article-title":"Mode of death in patients with heart failure and a preserved ejection fraction: Results from irbesartan heart failure with preserved ejection fraction study (I-Preserve) trial","volume":"30","author":"Zile","year":"2009","journal-title":"European Heart Journal"},{"issue":"12","key":"10.1002\/14651858.CD012721.pub3-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1161\/CIRCULATIONAHA.109.909614","article-title":"Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial","volume":"121","author":"Zile","year":"2010","journal-title":"Circulation"},{"issue":"23","key":"10.1002\/14651858.CD012721.pub3-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1161\/CIRCULATIONAHA.110.011031","article-title":"Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction","volume":"124","author":"Zile","year":"2011","journal-title":"Circulation"},{"issue":"7","key":"10.1002\/14651858.CD012721.pub3-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.cardfail.2005.04.003","article-title":"Rationale and design of a randomized trial to assess the effects of \u03b2-blocker in diastolic heart failure; Japanese Diastolic Heart Failure Study (J-DHF)","volume":"11","author":"Hori","year":"2005","journal-title":"Journal of Cardiac Failure"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0118|cit118","unstructured":"Japanese Diastolic Heart Failure Study upload.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000000411"},{"issue":"1","key":"10.1002\/14651858.CD012721.pub3-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/eurjhf\/hfs141","article-title":"Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF)","volume":"15","author":"Yamamoto","year":"2013","journal-title":"European Journal of Heart Failure"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/eurheartj\/eht308.805","article-title":"Left atrial dilatation as a predictive factor of beneficial response to carvedilol in patients with HFPEF: A finding from the Japanese Diastolic Heart Failure study (J-DHF)","volume":"34","author":"Yamamoto","year":"2013","journal-title":"European Heart Journal"},{"issue":"6","key":"10.1002\/14651858.CD012721.pub3-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.jjcc.2013.10.014","article-title":"Relation of risk factors with response to carvedilol in heart failure with preserved ejection fraction - a report from the Japanese Diastolic Heart Failure Study (J-DHF)","volume":"63","author":"Yamamoto","year":"2014","journal-title":"Journal of Cardiology"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0122|cit122","first-page":"48","article-title":"Effects of spironolactone on the left ventricular hypertrophy in chronic heart failure with preserved ejection fraction","volume":"17","author":"Karapysh","year":"2015","journal-title":"European Journal of Heart Failure"},{"issue":"5","key":"10.1002\/14651858.CD012721.pub3-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.jacc.2004.11.038","article-title":"Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart failure and preserved left ventricular ejection fraction","volume":"45","author":"Kasama","year":"2005","journal-title":"Journal of the American College of Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD012721.pub3-BIB0124|cit124","first-page":"477","article-title":"A randomized double-blind trial of enalapril in older patients with heart failure and preserved ejection fraction: effects on exercise tolerance and arterial distensibility","volume":"3","author":"Kitzman","year":"2010","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0125|cit125","unstructured":"Evaluation of enalapril versus placebo in patients with diastolic heart failure (PIE-I) clinicaltrials.gov\/show\/NCT01411735"},{"issue":"8","key":"10.1002\/14651858.CD012721.pub3-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.cardfail.2014.05.010","article-title":"Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction","volume":"20","author":"Kurrelmeyer","year":"2014","journal-title":"Journal of Cardiac Failure"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0127|cit127","unstructured":"Novel treatment for diastolic heart failure in women clinicaltrials.gov\/show\/NCT00206232"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0128|cit128","first-page":"866","article-title":"Eplerenone favourably alters collagen metabolism in diastolic heart failure","volume":"30","author":"Mak","year":"2009","journal-title":"European Heart Journal"},{"issue":"18","key":"10.1002\/14651858.CD012721.pub3-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1016\/j.jacc.2009.08.021","article-title":"Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone","volume":"54","author":"Mak","year":"2009","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0130|cit130","unstructured":"The effect of eplerenone and atorvastatin on markers of collagen turnover in diastolic heart failure clinicaltrials.gov\/show\/NCT00505336"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0131|cit131","unstructured":"Effects of spironolactone in heart failure with preserved ejection fraction: measured by CMR, echo, excercise capacity and quality of life questionaire www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-000867-10\/GB"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"e011521","DOI":"10.1161\/JAHA.118.011521","article-title":"Myocardial effects of aldosterone antagonism in heart failure with preserved ejection fraction","volume":"9","author":"McDiarmid","year":"2020","journal-title":"Journal of the American Heart Association"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0133|cit133","unstructured":"Evaluation of efficacy and safety of metoprolol in patients having heart failure with normal ejection fraction: a randomised, double-blind, placebo-controlled trial http:\/\/www.ctri.nic.in\/Clinicaltrials\/pmaindet2.php?trialid=1626"},{"issue":"3","key":"10.1002\/14651858.CD012721.pub3-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"124","DOI":"10.4103\/2229-3485.210449","article-title":"Evaluation of efficacy of metoprolol in patients having heart failure with preserved ejection fraction: A randomized, double-blind, placebo-controlled pilot trial","volume":"8","author":"Mittal","year":"2017","journal-title":"Perspectives in Clinical Research"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1161\/01.CIR.0000138680.89536.A9","article-title":"Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure","volume":"110","author":"Mottram","year":"2004","journal-title":"Circulation"},{"issue":"Suppl S","key":"10.1002\/14651858.CD012721.pub3-BIB0136|cit136","first-page":"47","article-title":"Myocardial dysfunction in hypertensive patients with isolated diastolic heart failure is reversible.A randomized trial of aldosterone antagonism","volume":"25","author":"Mottram","year":"2004","journal-title":"European Heart Journal"},{"issue":"2","key":"10.1002\/14651858.CD012721.pub3-BIB0137|cit137","first-page":"103","article-title":"Aldosterone receptor antagonists induce favorable cardiac remodeling in diastolic heart failure patients","volume":"59","author":"Orea-Tejeda","year":"2007","journal-title":"Revista de Investigacion Clinica"},{"issue":"10","key":"10.1002\/14651858.CD012721.pub3-BIB0138|cit138","first-page":"862","article-title":"Health-related quality of life in heart failure with preserved ejection fraction: the PARAGON-HF trial","volume":"7","author":"Chandra","year":"2019","journal-title":"JACC: Heart Failure"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0139|cit139","unstructured":"A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients (NYHA Class II-IV) with preserved ejection fraction www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-001747-31\/ES"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.119.044491","article-title":"Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: insights from PARAGON-HF","volume":"141","author":"McMurray","year":"2020","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0141|cit141","unstructured":"Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction (PARAGON-HF) clinicaltrials.gov\/ct2\/show\/NCT01920711"},{"issue":"17","key":"10.1002\/14651858.CD012721.pub3-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD012721.pub3-BIB0143|cit143","first-page":"471","article-title":"Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rational and design of the PARAGON-HF trial","volume":"5","author":"Solomon","year":"2017","journal-title":"JACC: Heart Failure"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0144|cit144","first-page":"e004962","article-title":"Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF trial","volume":"11","author":"Solomon","year":"2018","journal-title":"Circulation: Heart Failure"},{"issue":"11","key":"10.1002\/14651858.CD012721.pub3-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/S0735-1097(20)31537-0","article-title":"Influence of age on efficacy and safety of sacubitril\/valsartan in heart failure with preserved ejection fraction","volume":"75","author":"Vardeny","year":"2020","journal-title":"JACC"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0146|cit146","unstructured":"A randomized, double-blind controlled study comparing LCZ696 to medical therapy for comorbidities in HFpEF patients (PARALLAX) clinicaltrials.gov\/show\/NCT03066804"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0147|cit147","unstructured":"Pieske B PARALLAX (slideshow) ESC Congress 2020 - The Digital Experience"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/ehf2.12694","article-title":"Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial","volume":"7","author":"Wachter","year":"2020","journal-title":"ESC Heart Failure"},{"issue":"11","key":"10.1002\/14651858.CD012721.pub3-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1016\/S0735-1097(18)33206-6","article-title":"The angiotensin receptor neprilysin inhibitor (ARNI), sacubitril\/valsartan, improves left ventricular myocardial deformation in heart failure with preserved ejection fraction (PARAMOUNT trial)","volume":"71","author":"Biering-Sorensen","year":"2018","journal-title":"JACC"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0150|cit150","unstructured":"A twelve-week, randomized, double-blind, multi-center,parallel group, active controlled study to evaluate the efficacy, safety and tolerability of LCZ696 compared to valsartan in patients with chronic heart failure and preserved left-ventricular ejection fraction www.clinicaltrialsregister.eu\/ctr-search\/trial\/2009-010208-27\/IT"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0151|cit151","first-page":"A17434","article-title":"Abstract 17434: insulin-like growth factor binding protein-7 as a biomarker of diastolic dysfunction: results from the prospective comparison of ARNI with ARB on management of heart failure with preserved ejection fraction (PARAMOUNT) study","volume":"136","author":"Januzzi","year":"2017","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0152|cit152","unstructured":"LCZ696 compared to valsartan in patients with chronic heart failure and preserved left-ventricular ejection fraction clinicaltrials.gov\/ct2\/show\/NCT00887588"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD012721.pub3-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"e002551","DOI":"10.1161\/CIRCHEARTFAILURE.115.002551","article-title":"Plasma biomarkers reflecting profibrotic processes in heart failure with a preserved ejection fraction: data from the prospective comparison of ARNI with ARB on management of heart failure with preserved ejection fraction study","volume":"9","author":"Zile","year":"2016","journal-title":"Circulation. Heart Failure"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0155|cit155","unstructured":"Novartis Clinical Trial Results Database www.novctrd.com\/CtrdWeb\/displaypdf.nov?trialresultid=2460"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0156|cit156","unstructured":"Efficacy and safety of valsartan versus placebo on exercise tolerance in patients with heart failure clinicaltrials.gov\/show\/NCT00171106"},{"issue":"10","key":"10.1002\/14651858.CD012721.pub3-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/eurjhf\/hfp120","article-title":"A randomized, double-blind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction","volume":"11","author":"Parthasarathy","year":"2009","journal-title":"European Journal of Heart Failure"},{"issue":"5","key":"10.1002\/14651858.CD012721.pub3-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/eurjhf\/hfs049","article-title":"Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF study","volume":"14","author":"Cleland","year":"2012","journal-title":"European Journal of Heart Failure"},{"issue":"3","key":"10.1002\/14651858.CD012721.pub3-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S1388-9842(99)00039-2","article-title":"Perindopril for elderly people with chronic heart failure: the PEP-CHF study","volume":"1","author":"Cleland","year":"1999","journal-title":"European Journal of Heart Failure"},{"issue":"16","key":"10.1002\/14651858.CD012721.pub3-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1093\/eurheartj\/ehl250","article-title":"The perindopril in elderly people with chronic heart failure (PEP-CHF) study","volume":"27","author":"Cleland","year":"2006","journal-title":"European Heart Journal"},{"issue":"19","key":"10.1002\/14651858.CD012721.pub3-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1093\/eurheartj\/ehl249","article-title":"Renin angiotensin blockade in heart failure with preserved ejection fraction: The signal gets stronger","volume":"27","author":"McMurray","year":"2006","journal-title":"European Heart Journal"},{"issue":"11","key":"10.1002\/14651858.CD012721.pub3-BIB0162|cit162","first-page":"403","article-title":"Managing diastolic heart failure. Results of PEP-CHF","volume":"48","author":"Widimsky","year":"2006","journal-title":"Cor Vasa"},{"issue":"8","key":"10.1002\/14651858.CD012721.pub3-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.cardfail.2011.04.007","article-title":"Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF)","volume":"17","author":"Deswal","year":"2011","journal-title":"Journal of Cardiac Failure"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0164|cit164","unstructured":"Aldosterone antagonism in diastolic heart failure clinicaltrials.gov\/ct2\/show\/NCT00108251"},{"issue":"4","key":"10.1002\/14651858.CD012721.pub3-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/1755-5922.12196","article-title":"Targeting the sympatho-adrenergic link in chronic rheumatic mitral regurgitation: assessing the role of oral beta-blockers","volume":"34","author":"Sahoo","year":"2016","journal-title":"Cardiovascular Therapeutics"},{"issue":"9","key":"10.1002\/14651858.CD012721.pub3-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1093\/eurjhf\/hfp104","article-title":"Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial","volume":"11","author":"Cohen-Solal","year":"2009","journal-title":"European Journal of Heart Failure"},{"issue":"1","key":"10.1002\/14651858.CD012721.pub3-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.amjcard.2010.02.018","article-title":"Influence of diabetes mellitus and hyperglycemia on prognosis in patients > or =70 years old with heart failure and effects of nebivolol (data from the Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with heart failure [SENIORS])","volume":"106","author":"Boer","year":"2010","journal-title":"American Journal of Cardiology"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","article-title":"Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)","volume":"26","author":"Flather","year":"2005","journal-title":"European Heart Journal"},{"issue":"5","key":"10.1002\/14651858.CD012721.pub3-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1093\/eurheartj\/ehi735","article-title":"Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy","volume":"27","author":"Ghio","year":"2006","journal-title":"European Heart Journal"},{"issue":"5","key":"10.1002\/14651858.CD012721.pub3-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1093\/eurheartj\/ehi693","article-title":"Beta-blockade in heart failure: adding SENIORS to the mix","volume":"27","author":"Lindsey","year":"2006","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0171|cit171","first-page":"339","article-title":"Influence of systolic blood pressure on clinical outcome in elderly heart failure patients with preserved and reduced ejection fraction treated with nebivolol: data from SENIORS trial","volume":"35","author":"Montero-Perez-Barquero","year":"2014","journal-title":"European Heart Journal"},{"issue":"9","key":"10.1002\/14651858.CD012721.pub3-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/ejhf.136","article-title":"Influence of systolic blood pressure on clinical outcomes in elderly heart failure patients treated with nebivolol: data from the SENIORS trial","volume":"16","author":"Montero-Perez-Barquero","year":"2014","journal-title":"European Journal of Heart Failure"},{"issue":"10","key":"10.1002\/14651858.CD012721.pub3-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1093\/eurjhf\/hfs100","article-title":"Effect of nebivolol on outcome in elderly patients with heart failure and atrial fibrillation: insights from SENIORS","volume":"14","author":"Mulder","year":"2012","journal-title":"European Journal of Heart Failure"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0167-5273(02)00321-2","article-title":"Study of the effects of nebivolol intervention on outcomes and reshospitalisation in seniors with heart failure (SENIORS)","volume":"86","author":"Shibata","year":"2002","journal-title":"International Journal of Cardiology"},{"issue":"23","key":"10.1002\/14651858.CD012721.pub3-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.jacc.2009.02.046","article-title":"Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure)","volume":"53","author":"Veldhuisen","year":"2009","journal-title":"Journal of the American College of Cardiology"},{"issue":"6","key":"10.1002\/14651858.CD012721.pub3-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1016\/j.cardfail.2009.06.102","article-title":"Prevalence of anaemia and the effects of nebivolol on haemoglobin values in patients with chronic heart failure: Results from the SENIORS database","volume":"15","author":"Von Haehling","year":"2009","journal-title":"Journal of Cardiac Failure"},{"issue":"6","key":"10.1002\/14651858.CD012721.pub3-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/eurjhf\/hfr044","article-title":"Anaemia among patients with heart failure and preserved or reduced ejection fraction: results from the SENIORS study","volume":"13","author":"Haehling","year":"2011","journal-title":"European Journal of Heart Failure"},{"issue":"7","key":"10.1002\/14651858.CD012721.pub3-BIB0178|cit178","first-page":"400","article-title":"Short-term and long-term effects of bisoprolol on chronic heart failure related to rheumatic heart disease and atrial fibrillation","volume":"30","author":"Shu","year":"2005","journal-title":"Pharmacy and Therapeutics"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0179|cit179","first-page":"S78","article-title":"Quinapril in treatment of ambulatory patients with arterial hypertension and congestive heart failure and preserved systolic left ventricular function. (Results from the SNEGOVIK Study)","volume":"10","author":"Mareev","year":"2011","journal-title":"European Journal of Heart Failure. Supplement"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0180|cit180","unstructured":"Spironolactone in myocardial dysfunction with reduced exercise capacity www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=365563"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0181|cit181","first-page":"795","article-title":"Beneficial effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction-SpironolacTone in myocaRdial dysfunction with reduced exercise capacity (STRUCTURE)","volume":"37","author":"Kosmala","year":"2016","journal-title":"European Heart Journal"},{"issue":"17","key":"10.1002\/14651858.CD012721.pub3-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/j.jacc.2016.07.763","article-title":"Effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction","volume":"68","author":"Kosmala","year":"2016","journal-title":"Journal of the American College of Cardiology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012721.pub3-BIB0183|cit183","first-page":"120","article-title":"Usefulness of myocardial work measurement in the assessment of left ventricular systolic reserve response to spironolactone in heart failure with preserved ejection fraction","volume":"76","author":"Kosowski","year":"2018","journal-title":"Kardiologia Polska"},{"issue":"10","key":"10.1002\/14651858.CD012721.pub3-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1253\/circj.CJ-16-0577","article-title":"Influence of left ventricular ejection fraction on the effects of supplemental use of angiotensin receptor blocker olmesartan in hypertensive patients with heart failure","volume":"80","author":"Miura","year":"2016","journal-title":"Circulation Journal"},{"issue":"10","key":"10.1002\/14651858.CD012721.pub3-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"S159","DOI":"10.1016\/j.cardfail.2015.08.086","article-title":"The supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial","volume":"21","author":"Miura","year":"2015","journal-title":"Journal of Cardiac Failure"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0186|cit186","unstructured":"Supplemental benefit of angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) clinicaltrials.gov\/ct2\/show\/NCT00417222"},{"issue":"15","key":"10.1002\/14651858.CD012721.pub3-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/eurheartj\/ehu504","article-title":"Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: The supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial","volume":"36","author":"Sakata","year":"2015","journal-title":"European Heart Journal"},{"issue":"4","key":"10.1002\/14651858.CD012721.pub3-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.ejheart.2004.02.003","article-title":"Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC)","volume":"6","author":"Bergstrom","year":"2004","journal-title":"European Journal of Heart Failure"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.amjcard.2004.05.004","article-title":"Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction","volume":"94","author":"Takeda","year":"2004","journal-title":"American Journal of Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD012721.pub3-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jchf.2016.11.015","article-title":"Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial","volume":"5","author":"Anand","year":"2017","journal-title":"JACC. Heart Failure"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0191|cit191","doi-asserted-by":"crossref","DOI":"10.1161\/circ.132.suppl_3.14922","article-title":"Prognostic value of baseline BNP and NT-proBNP and its interaction with spironolactone in patients with heart failure and preserved ejection fraction in the TOPCAT trial","volume":"132","author":"Anand","year":"2015","journal-title":"Circulation"},{"issue":"11","key":"10.1002\/14651858.CD012721.pub3-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0735-1097(17)34273-0","article-title":"Influence of left ventricular ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction: The TOPCAT trial","volume":"69","author":"Bajaj","year":"2017","journal-title":"Journal of the American College of Cardiology"},{"issue":"3","key":"10.1002\/14651858.CD012721.pub3-BIB0193|cit193","first-page":"180","article-title":"Detection and management of geographic disparities in the TOPCAT trial: lessons learned and derivative recommendations","volume":"1","author":"Bristow","year":"2016","journal-title":"JACC: Basic to Translational Science"},{"issue":"6","key":"10.1002\/14651858.CD012721.pub3-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.ahj.2011.09.007","article-title":"Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction","volume":"162","author":"Desai","year":"2011","journal-title":"American Heart Journal"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0195|cit195","first-page":"662","article-title":"Incidence and predictors of doubling of serum creatinine during treatment of heart failure and preserved ejection fraction with spironolactone","volume":"36","author":"Desai","year":"2015","journal-title":"European Heart Journal"},{"issue":"12","key":"10.1002\/14651858.CD012721.pub3-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1002\/ejhf.621","article-title":"A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis","volume":"18","author":"Girerd","year":"2016","journal-title":"European Journal of Heart Failure"},{"issue":"2","key":"10.1002\/14651858.CD012721.pub3-BIB0197|cit197","first-page":"268","article-title":"Baseline distribution of participants with depression and impaired quality of life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial","volume":"8","author":"Hamo","year":"2015","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0198|cit198","first-page":"21","article-title":"Physical activity and prognosis in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial","volume":"21","author":"Hegde","year":"2017","journal-title":"Circulation"},{"issue":"6","key":"10.1002\/14651858.CD012721.pub3-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.jchf.2016.02.013","article-title":"QRS duration is a predictor of adverse outcomes in heart failure with preserved ejection fraction","volume":"4","author":"Joseph","year":"2016","journal-title":"JACC. Heart Failure"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD012721.pub3-BIB0200|cit200","first-page":"A11159","article-title":"Prolonged QRS duration predicts outcomes in heart failure with preserved ejection fraction","volume":"132","author":"Joseph","year":"2015","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0201|cit201","first-page":"530","article-title":"Spironolactone reduces all-cause mortality in women but not men with heart failure with preserved ejection fraction enrolled in TOPCAT from the Americas","volume":"19","author":"Kao","year":"2017","journal-title":"European Journal of Heart Failure"},{"issue":"8","key":"10.1002\/14651858.CD012721.pub3-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"JC6","DOI":"10.7326\/0003-4819-161-8-201410210-02006","article-title":"Spironolactone did not reduce cardiac outcomes in symptomatic heart failure with preserved ejection fraction","volume":"161","author":"Kelly","year":"2014","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0203|cit203","first-page":"530","article-title":"Sex differences in long-term health status in heart failure with preserved ejection fraction","volume":"19","author":"Kelsey Fling","year":"2017","journal-title":"European Journal of Heart Failure"},{"issue":"11","key":"10.1002\/14651858.CD012721.pub3-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S0735-1097(17)34271-7","article-title":"Paradoxical impact of proportional pulse pressure on mortality in patients with heart failure with preserved ejection fraction","volume":"69","author":"Kitai","year":"2017","journal-title":"Journal of the American College of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD012721.pub3-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1161\/CIRCULATIONAHA.114.012284","article-title":"International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction","volume":"131","author":"Kristensen","year":"2015","journal-title":"Circulation"},{"issue":"3","key":"10.1002\/14651858.CD012721.pub3-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jchf.2019.01.003","article-title":"Sex differences in outcomes and responses to spironolactone in heart failure with preserved ejection fraction: a secondary analysis of TOPCAT trial","volume":"7","author":"Merrill","year":"2019","journal-title":"JACC Heart Failure"},{"issue":"2","key":"10.1002\/14651858.CD012721.pub3-BIB0207|cit207","first-page":"181","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"371","author":"Morawietz","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0208|cit208","unstructured":"Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function (TOPCAT) clinicaltrials.gov\/ct2\/show\/NCT00094302"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012721.pub3-BIB0209|cit209","first-page":"759","article-title":"Risk of atrial fibrillation in heart failure with preserved ejection fraction: results from the treatment of cardiac function with an aldosterone antagonist (TOPCAT)","volume":"38","author":"Neefs","year":"2017","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s40256-019-00353-5","article-title":"Effect of spironolactone on atrial fibrillation in patients with heart failure with preserved ejection fraction: post-hoc analysis of the randomized, placebo-controlled TOPCAT trial","volume":"20","author":"Neefs","year":"2020","journal-title":"American Journal of Cardiovascular Drugs"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD012721.pub3-BIB0211|cit211","first-page":"A17975","article-title":"Anemia in heart failure with preserved ejection fraction: insights from the Topcat trial","volume":"132","author":"O'Meara","year":"2015","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0212|cit212","first-page":"30","article-title":"Echocardiographic predictors of atrial fibrillation in patients with heart failure with preserved ejection fraction","volume":"30","author":"O'Neal","year":"2017","journal-title":"European Heart Journal - Cardiovascular Imaging"},{"issue":"11","key":"10.1002\/14651858.CD012721.pub3-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1177\/2047487317708676","article-title":"Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction","volume":"24","author":"O'Neal","year":"2017","journal-title":"European Journal of Preventive Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD012721.pub3-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1001\/jamacardio.2015.0356","article-title":"Treatment of heart failure with preserved ejection fraction: reflections on its treatment with an aldosterone antagonist","volume":"1","author":"Pfeffer","year":"2016","journal-title":"JAMA Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD012721.pub3-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the Treatment of Preserved Cardia Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"issue":"24","key":"10.1002\/14651858.CD012721.pub3-BIB0216|cit216","first-page":"2709","article-title":"Treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT)","volume":"128","author":"Pfeffer","year":"2013","journal-title":"Circulation"},{"issue":"15","key":"10.1002\/14651858.CD012721.pub3-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0218|cit218","first-page":"26","article-title":"Peripheral artery disease and risk of adverse outcomes in heart failure with preserved ejection fraction","volume":"26","author":"Sandesara","year":"2017","journal-title":"Clinical Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD012721.pub3-BIB0219|cit219","first-page":"e002763","article-title":"Prognostic relevance of left atrial dysfunction in heart failure with preserved ejection fraction","volume":"9","author":"Santos","year":"2016","journal-title":"Circulation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012721.pub3-BIB0220|cit220","first-page":"A16989","article-title":"Impaired systolic function assessed by strain imaging predicts cardiovascular morbidity and mortality in heart failure with preserved ejection fraction","volume":"130","author":"Shah","year":"2014","journal-title":"Circulation"},{"issue":"5","key":"10.1002\/14651858.CD012721.pub3-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1161\/CIRCULATIONAHA.115.015884","article-title":"Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone","volume":"132","author":"Shah","year":"2015","journal-title":"Circulation"},{"issue":"5","key":"10.1002\/14651858.CD012721.pub3-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1161\/CIRCHEARTFAILURE.114.001583","article-title":"Cardiac structure and function and prognosis in heart failure with preserved ejection fraction","volume":"7","author":"Shah","year":"2014","journal-title":"Circulation. Heart Failure"},{"issue":"6","key":"10.1002\/14651858.CD012721.pub3-BIB0223|cit223","first-page":"1052","article-title":"Prognostic importance of changes in cardiac structure and function in heart failure with preserved ejection fraction and the impact of spironolactone","volume":"8","author":"Shah","year":"2015","journal-title":"Circulation"},{"issue":"1","key":"10.1002\/14651858.CD012721.pub3-BIB0224|cit224","first-page":"104","article-title":"Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial","volume":"7","author":"Shah","year":"2014","journal-title":"Circulation"},{"issue":"2","key":"10.1002\/14651858.CD012721.pub3-BIB0225|cit225","first-page":"184","article-title":"Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial","volume":"6","author":"Shah","year":"2013","journal-title":"Circulation"},{"issue":"5","key":"10.1002\/14651858.CD012721.pub3-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/eurheartj\/ehv464","article-title":"Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction","volume":"37","author":"Solomon","year":"2016","journal-title":"European Heart Journal"},{"issue":"12","key":"10.1002\/14651858.CD012721.pub3-BIB0227|cit227","first-page":"1022","article-title":"Influence of age on efficacy and safety of spironolactone in heart failure","volume":"7","author":"Vardeny","year":"2019","journal-title":"JACC: Heart Failure"},{"issue":"8S","key":"10.1002\/14651858.CD012721.pub3-BIB0228|cit228","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.cardfail.2019.07.036","article-title":"Influence of age on the efficacy and safety of spironolactone in heart failure with preserved ejection fraction","volume":"25","author":"Vardeny","year":"2019","journal-title":"Journal of Cardiac Failure"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0229|cit229","unstructured":"PIE II: pharmacological intervention in the elderly II clinicaltrials.gov\/show\/NCT00123955"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0230|cit230","first-page":"19","article-title":"Effect of spironolactone on exercise tolerance and arterial function in older adults with heart failure with preserved ejection fraction","volume":"19","author":"Upadhya","year":"2017","journal-title":"Journal of the American Geriatric Society"},{"issue":"2","key":"10.1002\/14651858.CD012721.pub3-BIB0231|cit231","first-page":"P1059","article-title":"Aldosterone antagonism increases post-exercise recruitment of systolic myocardial motion over left ventricular lateral wall in hypertensive patients with diastolic heart failure","volume":"122","author":"Wang","year":"2010","journal-title":"Circulation"},{"issue":"4","key":"10.1002\/14651858.CD012721.pub3-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"222","DOI":"10.5830\/CVJA-2019-022","article-title":"The effect of perindopril on echocardiographic parameters, NYHA functional class and serum NT-proBNP values in patients with diastolic heart failure","volume":"30","author":"Yuksek","year":"2019","journal-title":"Cardiovascular Journal of Africa"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0233|cit233","first-page":"S231","article-title":"The effect of perindopril treatment on echocardiographic diastolic and systolic functional parameters and serum NT-proBNP values in diastolic heart failure patients","volume":"11","author":"Yuksek","year":"2012","journal-title":"European Journal of Heart Failure. Supplements"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1023\/A:1025387702212","article-title":"The effect of quinapril on functional status of elderly patients with diastolic heart failure","volume":"17","author":"Zi","year":"2003","journal-title":"Cardiovascular Drugs and Therapy"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0235|cit235","unstructured":"Use of exercise and medical therapies to improve cardiac function among patients with exertional shortness of breath due to lung congestion www.anzctr.org.au\/ACTRN12610001087044.aspx"},{"issue":"15","key":"10.1002\/14651858.CD012721.pub3-BIB0236|cit236","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.jacc.2013.06.043","article-title":"Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial","volume":"62","author":"Kosmala","year":"2013","journal-title":"Journal of the American College of Cardiology"},{"issue":"10","key":"10.1002\/14651858.CD012721.pub3-BIB0237|cit237","doi-asserted-by":"crossref","first-page":"142C","DOI":"10.1016\/0002-9149(92)91375-E","article-title":"Study of the safety and efficacy of ACE inhibitors and their effects on 24-hour electrocardiographic monitoring in the treatment of moderate-to-severe heart failure: an interim analysis","volume":"70","author":"Adgey","year":"1992","journal-title":"American Journal of Cardiology"},{"issue":"12","key":"10.1002\/14651858.CD012721.pub3-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/00000446-200112000-00018","article-title":"Managing patients with heart failure","volume":"101","author":"Ammon","year":"2001","journal-title":"American Journal of Nursing"},{"issue":"4","key":"10.1002\/14651858.CD012721.pub3-BIB0239|cit239","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1161\/01.CIR.94.4.673","article-title":"Changes in early and late diastolic filling patterns induced by long-term adrenergic beta-blockade in patients with idiopathic dilated cardiomyopathy","volume":"94","author":"Andersson","year":"1996","journal-title":"Circulation"},{"issue":"8","key":"10.1002\/14651858.CD012721.pub3-BIB0240|cit240","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1053\/euhj.1998.1315","article-title":"Heart rate dependency of cardiac performance in heart failure patients treated with metoprolol","volume":"20","author":"Andersson","year":"1999","journal-title":"European Heart Journal"},{"issue":"6","key":"10.1002\/14651858.CD012721.pub3-BIB0241|cit241","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1136\/heart.84.6.599","article-title":"Early changes in longitudinal performance predict future improvement in global left ventricular function during long term beta adrenergic blockade","volume":"84","author":"Andersson","year":"2000","journal-title":"Heart"},{"issue":"8","key":"10.1002\/14651858.CD012721.pub3-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S0002-9149(96)00465-1","article-title":"Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES])","volume":"78","year":"1996","journal-title":"American Journal of Cardiology"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0243|cit243","first-page":"25","article-title":"Heart failure management in primary care: implications of the ATLAS study","volume":"100","year":"1999","journal-title":"International Journal of Clinical Practice. Supplement"},{"issue":"4","key":"10.1002\/14651858.CD012721.pub3-BIB0244|cit244","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1161\/01.CIR.101.4.378","article-title":"Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: the randomized evaluation of strategies for left ventricular dysfunction pilot study","volume":"101","year":"2000","journal-title":"Circulation"},{"issue":"2","key":"10.1002\/14651858.CD012721.pub3-BIB0245|cit245","first-page":"122","article-title":"Carvedilol saves lives - new data from landmark trials prove survival benefits in heart failure and post myocardial infarction","volume":"12","year":"2001","journal-title":"Cardiovascular Journal of South Africa"},{"issue":"1-2","key":"10.1002\/14651858.CD012721.pub3-BIB0246|cit246","first-page":"69","article-title":"Stress intolerance in diastolic dysfunction. A case for AT1 blocker?","volume":"144","year":"2002","journal-title":"MMW Fortschritte der Medizin"},{"issue":"49","key":"10.1002\/14651858.CD012721.pub3-BIB0247|cit247","first-page":"18","article-title":"When after myocardial infarction a pump weakness remains. ACE inhibitors and AT-1 blockers equivalent","volume":"145","year":"2003","journal-title":"MMW Fortschritte der Medizin"},{"issue":"5","key":"10.1002\/14651858.CD012721.pub3-BIB0248|cit248","first-page":"284","article-title":"CHARM shows benefits of Atacand for symptomatic heart failure","volume":"14","year":"2003","journal-title":"Cardiovascular Journal of South Africa"},{"issue":"26","key":"10.1002\/14651858.CD012721.pub3-BIB0249|cit249","first-page":"58","article-title":"Heart failure symptoms despite normal pump function. Beta blockers also improve diastole","volume":"145","year":"2003","journal-title":"MMW Fortschritte der Medizin"},{"issue":"25","key":"10.1002\/14651858.CD012721.pub3-BIB0250|cit250","first-page":"56","article-title":"NMR shows how beta blockers change the failing ventricle. Decreased size and better output performance","volume":"145","year":"2003","journal-title":"MMW Fortschritte der Medizin"},{"issue":"27-28","key":"10.1002\/14651858.CD012721.pub3-BIB0251|cit251","first-page":"44","article-title":"Heart failure after acute myocardial infarct. Early aldosterone blockade increases survival rate","volume":"147","year":"2005","journal-title":"MMW Fortschritte der Medizin"},{"issue":"47","key":"10.1002\/14651858.CD012721.pub3-BIB0252|cit252","first-page":"13","article-title":"Diastolic heart failure: AT1 blocker without effect","volume":"150","year":"2008","journal-title":"MMW Fortschritte der Medizin"},{"issue":"22","key":"10.1002\/14651858.CD012721.pub3-BIB0253|cit253","first-page":"48","article-title":"Misdiagnosed emergency: heart failure symptoms after infarct. Rapid aldosterone block can safe the tired heart","volume":"150","year":"2008","journal-title":"MMW Fortschritte der Medizin"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"f1290","DOI":"10.1136\/bmj.f1290","article-title":"Spironolactone made no difference to patients with mild diastolic heart failure","volume":"346","year":"2013","journal-title":"BMJ"},{"issue":"9049","key":"10.1002\/14651858.CD012721.pub3-BIB0255|cit255","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(97)80008-6","article-title":"Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease","volume":"349","author":"Australia\/New Zealand Heart Failure Research Collaborative Group","year":"1997","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD012721.pub3-BIB0256|cit256","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1161\/01.CIR.92.2.212","article-title":"Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group","volume":"92","author":"Australia\u2013New Zealand Heart Failure Research Collaborative Group","year":"1995","journal-title":"Circulation"},{"issue":"1","key":"10.1002\/14651858.CD012721.pub3-BIB0257|cit257","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S1071-9164(00)00007-5","article-title":"Effects of carvedilol on left ventricular regional wall motion in patients with heart failure caused by ischemic heart disease","volume":"6","author":"Doughty","year":"2000","journal-title":"Journal of Cardiac Failure"},{"issue":"5","key":"10.1002\/14651858.CD012721.pub3-BIB0258|cit258","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/S0735-1097(97)00012-0","article-title":"Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group","volume":"29","author":"Doughty","year":"1997","journal-title":"Journal of the American College of Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD012721.pub3-BIB0259|cit259","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1071-9164(98)90233-0","article-title":"Efficacy and safety of carvedilol in patients with chronic heart failure receiving concomitant amiodarone therapy. Australia\/New Zealand Heart Failure Research Collaborative Group","volume":"4","author":"Krum","year":"1998","journal-title":"Journal of Cardiac Failure"},{"issue":"2","key":"10.1002\/14651858.CD012721.pub3-BIB0260|cit260","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1161\/01.CIR.92.2.212","article-title":"Effects of carvedilol, a vasodilator-\u03b2-blocker, in patients with congestive heart failure due to ischemic heart disease","volume":"92","author":"Krum","year":"1995","journal-title":"Circulation"},{"issue":"6","key":"10.1002\/14651858.CD012721.pub3-BIB0261|cit261","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1161\/01.CIR.99.6.786","article-title":"Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction","volume":"99","author":"Richards","year":"1999","journal-title":"Circulation"},{"issue":"7","key":"10.1002\/14651858.CD012721.pub3-BIB0262|cit262","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/S0735-1097(01)01269-4","article-title":"Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction","volume":"37","author":"Richards","year":"2001","journal-title":"Journal of the American College of Cardiology"},{"issue":"Suppl B","key":"10.1002\/14651858.CD012721.pub3-BIB0263|cit263","first-page":"B36","article-title":"Left ventricular remodelling and improved long-term outcomes in chronic heart failure","volume":"19","author":"Sharpe","year":"1998","journal-title":"European Heart Journal"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD012721.pub3-BIB0264|cit264","first-page":"145","article-title":"Effect of combination therapy with angiotensin II type I receptor and aldosterone receptor blockers in heart failure","volume":"65","author":"Aoyama","year":"2007","journal-title":"Nippon Rinsho"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0265|cit265","first-page":"S200","article-title":"Influence of optimal beta blocker therapy on biomarkers of inflammation and proliferation in elderly patients with chronic stable heart failure","volume":"12","author":"Apostolovic","year":"2013","journal-title":"European Journal of Heart Failure"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0266|cit266","first-page":"ii213","article-title":"Beta-blockers in heart failure-influence on left ventricle remodeling. CIBIS ELD sub-study","volume":"15","author":"Apostolovic","year":"2014","journal-title":"European Heart Journal Cardiovascular Imaging"},{"issue":"2","key":"10.1002\/14651858.CD012721.pub3-BIB0267|cit267","first-page":"176","article-title":"Influence of optimization of beta blocker therapy in heart failure patients on natriuretic peptide levels and exercise capacity","volume":"3","author":"Apostolovic","year":"2014","journal-title":"European Heart Journal: Acute Cardiovascular Care"},{"issue":"2","key":"10.1002\/14651858.CD012721.pub3-BIB0268|cit268","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1249\/01.mss.0000241655.45500.c7","article-title":"The prognostic value of ventilatory efficiency with beta-blocker therapy in heart failure","volume":"39","author":"Arena","year":"2007","journal-title":"Medicine & Science in Sports & Exercise"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0269|cit269","first-page":"10","article-title":"Improved outcome in heart failure","volume":"100","author":"Armstrong","year":"1999","journal-title":"International Journal of Clinical Practice. Supplement"},{"issue":"2","key":"10.1002\/14651858.CD012721.pub3-BIB0270|cit270","doi-asserted-by":"crossref","first-page":"98","DOI":"10.2165\/00002512-199101020-00002","article-title":"Digoxin or angiotensin converting enzyme inhibitors for congestive heart failure in geriatric patients. Which is the preferred treatment?","volume":"1","author":"Aronow","year":"1991","journal-title":"Drugs and Aging"},{"issue":"11","key":"10.1002\/14651858.CD012721.pub3-BIB0271|cit271","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/S0002-9149(01)02092-6","article-title":"Effect of beta blockers alone, of angiotensin-converting enzyme inhibitors alone, and of beta blockers plus angiotensin-converting enzyme inhibitors on new coronary events and on congestive heart failure in older persons with healed myocardial infarcts and asymptomatic left ventricular systolic dysfunction","volume":"88","author":"Aronow","year":"2001","journal-title":"American Journal of Cardiology"},{"issue":"10","key":"10.1002\/14651858.CD012721.pub3-BIB0272|cit272","doi-asserted-by":"crossref","first-page":"A857","DOI":"10.1016\/S0735-1097(15)60857-9","article-title":"The effect of losartan on diastolic function, exercise capacity and symptoms in hypertrophic cardiomyopathy","volume":"65","author":"Axelsson","year":"2015","journal-title":"JACC"},{"issue":"3","key":"10.1002\/14651858.CD012721.pub3-BIB0273|cit273","first-page":"182","article-title":"Efficacy of spiranolactone therapy in patients with impaired left ventricular filling","volume":"14","author":"Balaban","year":"2007","journal-title":"MN Kardiyoloji"},{"issue":"15","key":"10.1002\/14651858.CD012721.pub3-BIB0274|cit274","first-page":"53","article-title":"Carvedilol for the intervention of the cardiac function and exercise tolerance in patients with congestive heart failure","volume":"9","author":"Bao","year":"2005","journal-title":"Chinese Journal of Clinical Rehabilitation"},{"issue":"17","key":"10.1002\/14651858.CD012721.pub3-BIB0275|cit275","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0002-9149(99)80353-1","article-title":"Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease","volume":"76","author":"Barr","year":"1995","journal-title":"American Journal of Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD012721.pub3-BIB0276|cit276","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1161\/CIRCULATIONAHA.108.844621","article-title":"Letter by Barrios et al regarding article, \"Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial\"","volume":"120","author":"Barrios","year":"2009","journal-title":"Circulation"},{"issue":"19","key":"10.1002\/14651858.CD012721.pub3-BIB0277|cit277","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1161\/01.CIR.0000070984.65122.9C","article-title":"How do beta-blockers improve ventricular function in patients with congestive heart failure?","volume":"107","author":"Barry","year":"2003","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0278|cit278","doi-asserted-by":"crossref","unstructured":"Heuvel FM Veldhuisen DJ Ent M Remme WJ Acute anti-ischemic effects of perindoprilat in men with coronary artery disease and their relation with left ventricular function American Journal of Cardiology 1999 83 3 332 6","DOI":"10.1016\/S0002-9149(98)00863-7"},{"issue":"20","key":"10.1002\/14651858.CD012721.pub3-BIB0279|cit279","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1161\/01.CIR.99.20.2658","article-title":"Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group","volume":"99","author":"Baruch","year":"1999","journal-title":"Circulation"},{"issue":"6","key":"10.1002\/14651858.CD012721.pub3-BIB0280|cit280","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.ahj.2004.06.001","article-title":"Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial (Val-HeFT)","volume":"148","author":"Baruch","year":"2004","journal-title":"American Heart Journal"},{"issue":"10","key":"10.1002\/14651858.CD012721.pub3-BIB0281|cit281","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1365-2362.2004.01400.x","article-title":"Aldosterone antagonism in heart failure: improvement of cardiac remodelling, endothelial dysfunction and platelet activation","volume":"34","author":"Bauersachs","year":"2004","journal-title":"European Journal of Clinical Investigation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012721.pub3-BIB0282|cit282","first-page":"48","article-title":"Valsartan improves symptoms and quality of life in patients with chronic heart failure","volume":"150","author":"Baumhakel","year":"2008","journal-title":"MMW Fortschritte der Medizin"},{"issue":"7","key":"10.1002\/14651858.CD012721.pub3-BIB0283|cit283","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/hrt.2003.015552","article-title":"Effects of carvedilol on left ventricular remodelling in chronic stable heart failure: a cardiovascular magnetic resonance study","volume":"90","author":"Bellenger","year":"2004","journal-title":"Heart"},{"issue":"5","key":"10.1002\/14651858.CD012721.pub3-BIB0284|cit284","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S0002-9149(00)01439-9","article-title":"Are angiotensin II receptor blockers more efficacious than placebo in heart failure? Implications of ELITE-2","volume":"87","author":"Berry","year":"2001","journal-title":"American Journal of Cardiology"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD012721.pub3-BIB0285|cit285","first-page":"V101","article-title":"Treating diastolic heart failure: the role of ACE inhibitors","volume":"18","author":"Bettencourt","year":"1999","journal-title":"Revista Portuguesa de Cardiologia"},{"issue":"16","key":"10.1002\/14651858.CD012721.pub3-BIB0286|cit286","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1016\/j.jacc.2016.02.033","article-title":"Early aldosterone blockade in acute myocardial infarction: The ALBATROSS randomized clinical trial","volume":"67","author":"Beygui","year":"2016","journal-title":"Journal of the American College of Cardiology"},{"issue":"9","key":"10.1002\/14651858.CD012721.pub3-BIB0287|cit287","first-page":"17","article-title":"Effect of lisinopril on cardiac remodeling in patients with cardiosclerosis after myocardial infarction and signs of chronic heart failure","volume":"43","author":"Blagodar","year":"2003","journal-title":"Kardiologiia"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0288|cit288","first-page":"157","article-title":"Treatment of heart failure: what - when - how?","volume":"96","author":"Blomer","year":"1990","journal-title":"Verhandlungen Der Deutschen Gesellschaft Fur Innere Medizin"},{"issue":"21","key":"10.1002\/14651858.CD012721.pub3-BIB0289|cit289","article-title":"Double-blind, randomized comparison of zofenopril vs. ramipril in MI patients treated with ASA: The SMILE 4 study and subgroup analysis","volume":"124","author":"Borghi","year":"2011","journal-title":"Circulation"},{"issue":"5","key":"10.1002\/14651858.CD012721.pub3-BIB0290|cit290","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/clc.4960130506","article-title":"Captopril improves hemodynamic response to static exercise in patients with congestive heart failure: a double-blind, placebo-controlled, randomized trial","volume":"13","author":"Borgi","year":"1990","journal-title":"Clinical Cardiology"},{"issue":"8","key":"10.1002\/14651858.CD012721.pub3-BIB0291|cit291","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.tcm.2014.07.006","article-title":"MY APPROACH to heart failure with preserved ejection fraction","volume":"24","author":"Borlaug","year":"2014","journal-title":"Trends in Cardiovascular Medicine"},{"issue":"3","key":"10.1002\/14651858.CD012721.pub3-BIB0292|cit292","first-page":"76","article-title":"ACE-inhibitors and heart failure. Results of studies of left ventricular dysfunction","volume":"15","author":"Bornkessel","year":"1992","journal-title":"Medizinische Monatsschrift f\u00fcr Pharmazeuten"},{"issue":"Spec No 4","key":"10.1002\/14651858.CD012721.pub3-BIB0293|cit293","first-page":"89","article-title":"Perindopril and chronic heart failure","volume":"84","author":"Bounhoure J","year":"1991","journal-title":"Archives Des Maladies Du Coeur Et Des Vaisseaux"},{"issue":"20","key":"10.1002\/14651858.CD012721.pub3-BIB0294|cit294","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa042739","article-title":"Angiotensin-converting-enzyme inhibition in stable coronary artery disease","volume":"351","author":"Braunwald","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD012721.pub3-BIB0295|cit295","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/BF01883867","article-title":"Low-dose enalapril in severe chronic heart failure","volume":"3","author":"Brilla","year":"1989","journal-title":"Cardiovascular Drugs and Therapy"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012721.pub3-BIB0296|cit296","first-page":"44","article-title":"Low-dose enalapril in severe chronic heart failure","volume":"80","author":"Brilla","year":"1991","journal-title":"Zeitschrift f\u00fcr Kardiologie"},{"issue":"4","key":"10.1002\/14651858.CD012721.pub3-BIB0297|cit297","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1161\/01.CIR.89.4.1632","article-title":"Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Bucindolol Investigators","volume":"89","author":"Bristow","year":"1994","journal-title":"Circulation"},{"issue":"11","key":"10.1002\/14651858.CD012721.pub3-BIB0298|cit298","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1161\/01.CIR.94.11.2807","article-title":"Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators","volume":"94","author":"Bristow","year":"1996","journal-title":"Circulation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012721.pub3-BIB0299|cit299","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1097\/00005344-198700002-00012","article-title":"Long-term treatment of severe chronic heart failure with captopril: a double-blind, randomized, placebo-controlled, long-term study","volume":"9","author":"Bussmann","year":"1987","journal-title":"Journal of Cardiovascular Pharmacology"},{"issue":"9","key":"10.1002\/14651858.CD012721.pub3-BIB0300|cit300","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1001\/jamacardio.2017.2198","article-title":"Efficacy and safety of spironolactone in acute heart failure: the ATHENA-HF randomized clinical trial","volume":"2","author":"Butler","year":"2017","journal-title":"JAMA Cardiology"},{"issue":"9","key":"10.1002\/14651858.CD012721.pub3-BIB0301|cit301","first-page":"726","article-title":"Rationale and design of the ATHENA-HF trial: aldosterone targeted neurohormonal combined with natriuresis therapy in heart failure","volume":"4","author":"Butler","year":"2016","journal-title":"Journal of the American College of Cardiology. Heart Failure"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0302|cit302","doi-asserted-by":"crossref","first-page":"10978","DOI":"10.1016\/j.cjca.2019.01.022","article-title":"Spironolactone in acute heart failure patients with renal dysfunction in risk factors for diuretic resistance: from the ATHENA-HF trial","volume":"35","author":"Greene","year":"2019","journal-title":"Canadian Journal of Cardiology"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0303|cit303","unstructured":"Study of high-dose spironolactone vs placebo therapy in acute heart failure (ATHENA-HF) clinicaltrials.gov\/show\/NCT02235077"},{"issue":"2","key":"10.1002\/14651858.CD012721.pub3-BIB0304|cit304","first-page":"51","article-title":"Question: does beta-blocker therapy improve outcomes in patients with congestive heart failure with normal left ventricular function (diastolic dysfunction)?","volume":"103","author":"Cafaro","year":"2010","journal-title":"Journal of the Oklahoma State Medical Association"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD012721.pub3-BIB0305|cit305","first-page":"V97","article-title":"Treating diastolic heart failure: the role of beta-blockers","volume":"18","author":"Cardoso","year":"1999","journal-title":"Revista Portuguesa de Cardiologia"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0306|cit306","first-page":"571","article-title":"Effect of carvedilol in patients with or without renal impairment after myocardial infarction:analysis of the carvedilol post-infarct survival control in left ventricular dysfunction (CAPRICORN) study","volume":"31","author":"Castagno","year":"2010","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0307|cit307","unstructured":"Effect of allisartan isoproxil tablets on ventricular remodeling and cardiac function in patients with chronic congestive heart failure www.chictr.org.cn\/showprojen.aspx?proj=27554"},{"issue":"1","key":"10.1002\/14651858.CD012721.pub3-BIB0308|cit308","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1067\/mnc.2001.109452","article-title":"Iodine-123 MIBG imaging before treatment of heart failure with carvedilol to predict improvement of left ventricular function and exercise capacity","volume":"8","author":"Choi","year":"2001","journal-title":"Journal of Nuclear Cardiology"},{"issue":"10","key":"10.1002\/14651858.CD012721.pub3-BIB0309|cit309","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.amjmed.2003.12.033","article-title":"Effects of ACE gene insertion\/deletion polymorphism on response to spironolactone in patients with chronic heart failure","volume":"116","author":"Cicoira","year":"2004","journal-title":"American Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD012721.pub3-BIB0310|cit310","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0735-1097(02)01965-4","article-title":"Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure","volume":"40","author":"Cicoira","year":"2002","journal-title":"Journal of the American College of Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD012721.pub3-BIB0311|cit311","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1136\/hrt.52.5.530","article-title":"Captopril in heart failure. A double blind controlled trial","volume":"52","author":"Cleland","year":"1984","journal-title":"British Heart Journal"},{"issue":"2","key":"10.1002\/14651858.CD012721.pub3-BIB0312|cit312","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1388-9842(99)00024-0","article-title":"The carvedilol hibernation reversible ischaemia trial; marker of success (CHRISTMAS). The CHRISTMAS Study Steering Committee and Investigators","volume":"1","author":"Cleland","year":"1999","journal-title":"European Journal of Heart failure"},{"issue":"6","key":"10.1002\/14651858.CD012721.pub3-BIB0313|cit313","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S1388-9842(01)00211-2","article-title":"ACE inhibitors for 'diastolic' heart failure? reasons not to jump to premature conclusions about the efficacy of ACE inhibitors among older patients with heart failure","volume":"3","author":"Cleland","year":"2001","journal-title":"European Journal of Heart Failure"},{"issue":"9377","key":"10.1002\/14651858.CD012721.pub3-BIB0314|cit314","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0140-6736(03)13801-9","article-title":"Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial","volume":"362","author":"Cleland","year":"2003","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD012721.pub3-BIB0315|cit315","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.ejheart.2004.09.001","article-title":"Clinical trials update from the European Society of Cardiology: SENIORS, ACES, PROVE-IT, ACTION, and the HF-ACTION trial","volume":"6","author":"Cleland","year":"2004","journal-title":"European Journal of Heart Failure"},{"issue":"6","key":"10.1002\/14651858.CD012721.pub3-BIB0316|cit316","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.ejheart.2006.09.009","article-title":"Clinical trials update from the joint European Society and World Congress of Cardiology meeting: PEP-CHF, ACCLAIM and the HHH study","volume":"8","author":"Cleland","year":"2006","journal-title":"European Journal of Heart Failure"},{"issue":"6-7","key":"10.1002\/14651858.CD012721.pub3-BIB0317|cit317","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.ejheart.2007.04.004","article-title":"Clinical trials update from the American College of Cardiology 2007: ALPHA, EVEREST, FUSION II, VALIDD, PARR-2, REMODEL, SPICE, COURAGE, COACH, REMADHE, pro-BNP for the evaluation of dyspnoea and THIS-diet","volume":"9","author":"Cleland","year":"2007","journal-title":"European Journal of Heart Failure"},{"issue":"2","key":"10.1002\/14651858.CD012721.pub3-BIB0318|cit318","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/eurjhf\/hfp199","article-title":"Clinical trials update from the American Heart Association meeting 2009: HEAAL, FAIR-HF, J-CHF, HeartMate II, PACE and a meta-analysis of dose-ranging studies of beta-blockers in heart failure","volume":"12","author":"Cleland","year":"2010","journal-title":"European Journal of Heart Failure"},{"issue":"12","key":"10.1002\/14651858.CD012721.pub3-BIB0319|cit319","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1093\/eurjhf\/hfr149","article-title":"Clinical trials update from the European Society of Cardiology Meeting 2011: ARISTOTLE, SMART-AV: QLV substudy, SHIFT: Echocardiography and quality of life substudies, European CRT Survey, and Basic Science Update","volume":"13","author":"Cleland","year":"2011","journal-title":"European Journal of Heart Failure"},{"issue":"40","key":"10.1002\/14651858.CD012721.pub3-BIB0320|cit320","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1093\/eurheartj\/eht366","article-title":"Diabetes, aliskiren, and heart failure: Let's bring ASTRONAUT down to earth","volume":"34","author":"Cleland","year":"2013","journal-title":"European Heart Journal"},{"issue":"11","key":"10.1002\/14651858.CD012721.pub3-BIB0321|cit321","first-page":"1796","article-title":"Effects of carvedilol on myocardial sympathetic innervation in patients with chronic heart failure","volume":"46","author":"Cohen-Solal","year":"2005","journal-title":"Journal of Nuclear Medicine"},{"issue":"3","key":"10.1002\/14651858.CD012721.pub3-BIB0322|cit322","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/BF00880162","article-title":"ACE inhibitors","volume":"7","author":"Cohn","year":"1993","journal-title":"Cardiovascular Drugs and Therapy"},{"issue":"11","key":"10.1002\/14651858.CD012721.pub3-BIB0323|cit323","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/oxfordjournals.eurheartj.a014737","article-title":"Slowing the progression of heart failure","volume":"17","author":"Cohn","year":"1996","journal-title":"European Heart Journal"},{"issue":"7","key":"10.1002\/14651858.CD012721.pub3-BIB0324|cit324","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1056\/NEJM199608153350707","article-title":"The management of chronic heart failure","volume":"335","author":"Cohn","year":"1996","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD012721.pub3-BIB0325|cit325","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jacc.2007.04.063","article-title":"Myocardial structural effects of aldosterone receptor antagonism in heart failure","volume":"50","author":"Cohn","year":"2007","journal-title":"JACC"},{"issue":"12","key":"10.1002\/14651858.CD012721.pub3-BIB0326|cit326","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.ejheart.2008.10.002","article-title":"Clinical trials update from European Society of Cardiology meeting 2008: TIME-CHF, BACH, BEAUTIFUL, GISSI-HF, and HOME-HF","volume":"10","author":"Coletta","year":"2008","journal-title":"European Journal of Heart Failure"},{"issue":"2","key":"10.1002\/14651858.CD012721.pub3-BIB0327|cit327","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/eurjhf\/hfn047","article-title":"Clinical trials update from the Heart Failure Society of America and the American Heart Association meetings in 2008: SADHART-CHF, COMPARE, MOMENTUM, thyroid hormone analogue study, HF-ACTION, I-PRESERVE, beta-interferon study, BACH, and ATHENA","volume":"11","author":"Coletta","year":"2009","journal-title":"European Journal of Heart Failure"},{"issue":"1","key":"10.1002\/14651858.CD012721.pub3-BIB0328|cit328","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0041-1345(01)02717-8","article-title":"Effect of carvedilol therapy on functional mitral regurgitation, ventricular remodeling, and contractility in patients with heart failure due to left ventricular systolic dysfunction","volume":"34","author":"Comin-Colet","year":"2002","journal-title":"Transplantation Proceedings"},{"issue":"2","key":"10.1002\/14651858.CD012721.pub3-BIB0329|cit329","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/1071-9164(95)90012-8","article-title":"Atrial natriuretic peptide ANP(1-98) and ANP(99-126) in patients with severe chronic congestive heart failure: relation to echocardiographic measurements. A subgroup analysis from the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"1","author":"Eriksson","year":"1995","journal-title":"Journal of Cardiac Failure"},{"issue":"4","key":"10.1002\/14651858.CD012721.pub3-BIB0330|cit330","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/0002-9149(92)91194-9","article-title":"Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study Trial)","volume":"70","author":"Ljungman","year":"1992","journal-title":"American Journal of Cardiology"},{"issue":"2","key":"10.1002\/14651858.CD012721.pub3-BIB0331|cit331","doi-asserted-by":"crossref","first-page":"60A","DOI":"10.1016\/S0002-9149(88)80087-0","article-title":"Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"62","author":"Swedberg","year":"1988","journal-title":"American Journal of Cardiology"},{"issue":"23","key":"10.1002\/14651858.CD012721.pub3-BIB0332|cit332","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","author":"The CONSENSUS Trial Study Group","year":"1987","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD012721.pub3-BIB0333|cit333","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/clc.4960190705","article-title":"Effect of enalapril initiated early after acute myocardial infarction on heart failure parameters, with reference to clinical class and echocardiographic determinants. CONSENSUS II Multi-Echo Study Group","volume":"19","author":"Edner","year":"1996","journal-title":"Clinical Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD012721.pub3-BIB0334|cit334","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/clc.4960280102","article-title":"Management of heart failure and left ventricular systolic dysfunction following acute myocardial infarction","volume":"28","author":"Conti","year":"2005","journal-title":"Clinical Cardiology"},{"issue":"3","key":"10.1002\/14651858.CD012721.pub3-BIB0335|cit335","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000139040","article-title":"Effect of cilazapril on exercise tolerance in congestive heart failure","volume":"46","author":"Corder","year":"1993","journal-title":"Pharmacology"},{"issue":"2","key":"10.1002\/14651858.CD012721.pub3-BIB0336|cit336","first-page":"101","article-title":"Clinical inquiries. Which medications benefit patients with diastolic heart failure?","volume":"60","author":"Crouse","year":"2011","journal-title":"Journal of Family Practice"},{"issue":"34","key":"10.1002\/14651858.CD012721.pub3-BIB0337|cit337","first-page":"2348","article-title":"Treatment of heart failure and preserved systolic function","volume":"104","author":"Dahlstrom","year":"2007","journal-title":"Lakartidningen"},{"issue":"6","key":"10.1002\/14651858.CD012721.pub3-BIB0338|cit338","first-page":"1585","article-title":"Effect of chronic angiotensin II type I receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic variables in patients with heart failure","volume":"86","author":"Davie","year":"2001","journal-title":"Thrombosis and Haemostasis"},{"issue":"3","key":"10.1002\/14651858.CD012721.pub3-BIB0339|cit339","doi-asserted-by":"crossref","first-page":"M148","DOI":"10.1093\/geronj\/49.3.M148","article-title":"Captopril treatment of chronic heart failure in the very old","volume":"49","author":"DeBock","year":"1994","journal-title":"Journal of Gerontology"},{"issue":"6","key":"10.1002\/14651858.CD012721.pub3-BIB0340|cit340","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/BF03654848","article-title":"Beta blockers therapy is associated with improved left ventricular systolic function and sustained exercise capacity in elderly patients with heart failure. CIBIS-ELD sub-study","volume":"24","author":"Dekleva","year":"2012","journal-title":"Aging Clinical and Experimental Research"},{"issue":"14","key":"10.1002\/14651858.CD012721.pub3-BIB0341|cit341","doi-asserted-by":"crossref","first-page":"E259","DOI":"10.1016\/S0735-1097(11)60259-3","article-title":"The impact of the rapid use of beta-blockers on ventricular remodeling and mortality in end-stage heart failure","volume":"57","author":"De Melo","year":"2011","journal-title":"JACC"},{"issue":"4","key":"10.1002\/14651858.CD012721.pub3-BIB0342|cit342","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1067\/mhj.2001.118468","article-title":"Reliability, validity, and responsiveness of the six-minute walk test in patients with heart failure","volume":"142","author":"Demers","year":"2001","journal-title":"American Heart Journal"},{"issue":"4","key":"10.1002\/14651858.CD012721.pub3-BIB0343|cit343","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jacc.2013.03.075","article-title":"Heart failure with preserved ejection fraction: Time for a new approach?","volume":"62","author":"Desai","year":"2013","journal-title":"JACC"},{"issue":"8","key":"10.1002\/14651858.CD012721.pub3-BIB0344|cit344","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.cardfail.2010.06.026","article-title":"Randomized trial of aldosterone antagonism in diastolic heart failure (RAAM-DHF)","volume":"16","author":"Deswal","year":"2010","journal-title":"Journal of Cardiac Failure"},{"issue":"2","key":"10.1002\/14651858.CD012721.pub3-BIB0345|cit345","first-page":"128","article-title":"Cardiovascular pharmacology (IX). Angiotensin-converting enzyme inhibitors in hypertension and heart failure","volume":"48","author":"Teresa","year":"1995","journal-title":"Revista Espanola de Cardiologia"},{"issue":"6","key":"10.1002\/14651858.CD012721.pub3-BIB0346|cit346","first-page":"675","article-title":"Ramipril in combination with irbesartan for treatment of chronic heart failure in patients with rheumatic heart disease","volume":"29","author":"Ding","year":"2008","journal-title":"Academic Journal of Second Military Medical University"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0347|cit347","first-page":"31","article-title":"Ramipril treatment of heart failure in disseminated forms of pulmonary tuberculosis","volume":"2","author":"Ditiatkov","year":"1999","journal-title":"Problemy Tuberkuleza"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012721.pub3-BIB0348|cit348","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.revmed.2008.03.022","article-title":"Heart failure with preserved ejection fraction","volume":"29","author":"Donal","year":"2008","journal-title":"La Revue de M\u00e9decine Interne"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0349|cit349","first-page":"364","article-title":"Beta blockers in heart failure with preserved left ventricle ejection fraction","volume":"17","author":"Dragana Stanojevic","year":"2015","journal-title":"European Journal of Heart Failure"},{"issue":"7","key":"10.1002\/14651858.CD012721.pub3-BIB0350|cit350","first-page":"331","article-title":"Renin-angiotensin system antagonists associated with reduced [corrected] mortality in diastolic heart failure","volume":"110","author":"Edner","year":"2013","journal-title":"Lakartidningen"},{"issue":"1","key":"10.1002\/14651858.CD012721.pub3-BIB0351|cit351","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/1071-9164(94)90007-8","article-title":"Functional importance of myocardial relaxation in patients with congestive heart failure","volume":"1","author":"Eichhorn","year":"1994","journal-title":"Journal of Cardiac Failure"},{"issue":"19","key":"10.1002\/14651858.CD012721.pub3-BIB0352|cit352","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1161\/01.CIR.0000097111.00170.7B","article-title":"Myocardial contractile reserve by dobutamine stress echocardiography predicts improvement in ejection fraction with beta-blockade in patients with heart failure: the Beta-Blocker Evaluation of Survival Trial (BEST)","volume":"108","author":"Eichhorn","year":"2003","journal-title":"Circulation"},{"issue":"24","key":"10.1002\/14651858.CD012721.pub3-BIB0353|cit353","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1055\/s-2005-870846","article-title":"Ivabradine -- a novel approach for heart rate lowering","volume":"130","author":"Er","year":"2005","journal-title":"Deutsche Medizinische Wochenschrift"},{"issue":"3","key":"10.1002\/14651858.CD012721.pub3-BIB0354|cit354","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1177\/204748739900600304","article-title":"Left ventricular remodelling during treatment with beta-blockers","volume":"6","author":"Ertl","year":"1999","journal-title":"Journal of Cardiovascular Risk"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0355|cit355","unstructured":"A Pilot study to assess the effects of beta-blockade on exercise capacity and BNP levels in patients with predominantly diastolic heart failure www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2004-004169-13"},{"issue":"2","key":"10.1002\/14651858.CD012721.pub3-BIB0356|cit356","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.amjcard.2008.09.064","article-title":"Comparison of beta blocker and digoxin alone and in combination for management of patients with atrial fibrillation and heart failure","volume":"103","author":"Fauchier","year":"2009","journal-title":"American Journal of Cardiology"},{"issue":"8","key":"10.1002\/14651858.CD012721.pub3-BIB0357|cit357","first-page":"CR341","article-title":"Effects of the addition of a low dose of spironolactone on brain natriuretic peptide plasma level and cardiopulmonary function in patients with moderate congestive heart failure","volume":"9","author":"Feola","year":"2003","journal-title":"Medical Science Monitor"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0358|cit358","first-page":"S222","article-title":"Mineralocorticoid receptor antagonism in patients with coronary artery disease and preserved ejection fraction-a randomized, double-blind trial","volume":"12","author":"Flammer","year":"2013","journal-title":"European Journal of Heart Failure"},{"issue":"2","key":"10.1002\/14651858.CD012721.pub3-BIB0359|cit359","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jchf.2015.12.009","article-title":"Understanding mechanisms of action of beta-blockers in heart failure with reduced and preserved ejection fraction","volume":"4","author":"Flather","year":"2016","journal-title":"JACC Heart Failure"},{"issue":"4","key":"10.1002\/14651858.CD012721.pub3-BIB0360|cit360","first-page":"829","article-title":"Combined administration of AT1-receptor antagonists and beta-blockers in patients with chronic heart insufficiency","volume":"46","author":"Flesch","year":"2006","journal-title":"Internistische Praxis"},{"issue":"18","key":"10.1002\/14651858.CD012721.pub3-BIB0361|cit361","first-page":"747","article-title":"Beta-blockers in cardiac insufficiency. Time to reconsider?","volume":"126","author":"Follath","year":"1996","journal-title":"Schweizer Medizinische Wochenschrift"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0362|cit362","first-page":"16E","article-title":"Questions and answers","volume":"16 Suppl E","author":"Fonarow","year":"2004","journal-title":"Journal of Invasive Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD012721.pub3-BIB0363|cit363","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.ahj.2007.06.002","article-title":"Effects of carvedilol early after myocardial infarction: analysis of the first 30 days in Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN)","volume":"154","author":"Fonarow","year":"2007","journal-title":"American Heart Journal"},{"issue":"3","key":"10.1002\/14651858.CD012721.pub3-BIB0364|cit364","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/204748739900600303","article-title":"The influence of beta-adrenergic blocking drugs on morbidity and mortality in heart failure","volume":"6","author":"Fowler","year":"1999","journal-title":"Journal of Cardiovascular Risk"},{"issue":"3","key":"10.1002\/14651858.CD012721.pub3-BIB0365|cit365","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1054\/jcaf.2002.124730","article-title":"African-American Heart Failure Trial (A-HeFT): rationale, design, and methodology","volume":"8","author":"Franciosa","year":"2002","journal-title":"Journal of Cardiac Failure"},{"issue":"2","key":"10.1002\/14651858.CD012721.pub3-BIB0366|cit366","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/BF03029771","article-title":"Effectiveness of long-term beta-blocker therapy for dilated cardiomyopathy--echocardiographical follow-up","volume":"5","author":"Fukunami","year":"1991","journal-title":"Cardiovascular Drugs and Therapy"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0367|cit367","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S1261-694X(07)92141-0","article-title":"Treatment of heart failure with preserved ejection fraction","volume":"158","author":"Galinier","year":"2007","journal-title":"Archives des Maladies du Coeur et des Vaisseaux - Pratique"},{"issue":"2","key":"10.1002\/14651858.CD012721.pub3-BIB0368|cit368","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2710.2006.00606.x","article-title":"Dosage dependent hormonal counter regulation to combination therapy in patients with left ventricular dysfunction","volume":"31","author":"Galloe","year":"2006","journal-title":"Journal of Clinical Pharmacology and Therapy"},{"issue":"5","key":"10.1002\/14651858.CD012721.pub3-BIB0369|cit369","first-page":"1132","article-title":"Effect of metoprolol on the expression of GRK2 in lymphocyte of advanced elderly patients with chronic heart failure","volume":"30","author":"Gao","year":"2010","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"issue":"12","key":"10.1002\/14651858.CD012721.pub3-BIB0370|cit370","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1136\/heart.89.12.1442","article-title":"Importance of beta blockade in the treatment of advanced heart failure","volume":"89","author":"Gardner","year":"2003","journal-title":"Heart"},{"issue":"1","key":"10.1002\/14651858.CD012721.pub3-BIB0371|cit371","doi-asserted-by":"crossref","first-page":"18","DOI":"10.7861\/clinmedicine.4-1-18","article-title":"The treatment of chronic heart failure due to left ventricular systolic dysfunction","volume":"4","author":"Gardner","year":"2004","journal-title":"Clinical Medicine"},{"issue":"13","key":"10.1002\/14651858.CD012721.pub3-BIB0372|cit372","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1161\/01.CIR.0000012546.20194.33","article-title":"Metoprolol CR\/XL in female patients with heart failure: analysis of the experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF)","volume":"105","author":"Ghali","year":"2002","journal-title":"Circulation"},{"issue":"3","key":"10.1002\/14651858.CD012721.pub3-BIB0373|cit373","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.ahj.2009.07.003","article-title":"The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction","volume":"158","author":"Gheorghiade","year":"2009","journal-title":"American Heart Journal"},{"issue":"1","key":"10.1002\/14651858.CD012721.pub3-BIB0374|cit374","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1161\/01.CIR.90.1.220","article-title":"Effect of intense angiotensin II suppression on the diuretic response to furosemide during chronic ACE inhibition","volume":"90","author":"Good","year":"1994","journal-title":"Circulation"},{"issue":"23","key":"10.1002\/14651858.CD012721.pub3-BIB0375|cit375","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1161\/01.CIR.99.23.2983","article-title":"Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure","volume":"99","author":"Goodfield","year":"1999","journal-title":"Circulation"},{"issue":"12","key":"10.1002\/14651858.CD012721.pub3-BIB0376|cit376","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/S0002-9149(96)00640-6","article-title":"Hemodynamic effects of the class III antiarrhythmic drug, d-sotalol, in patients with congestive heart failure","volume":"78","author":"Gottlieb","year":"1996","journal-title":"American Journal of Cardiology"},{"issue":"12","key":"10.1002\/14651858.CD012721.pub3-BIB0377|cit377","first-page":"1313","article-title":"Do angiotensin receptor blockers increased the risk of myocardial infarction? The landscape after ONTARGET study","volume":"66","author":"Grajek","year":"2008","journal-title":"Kardiologia Polska"},{"issue":"7","key":"10.1002\/14651858.CD012721.pub3-BIB0378|cit378","first-page":"40","article-title":"Left ventricular dysfunction: Effects of long-term enalapril therapy on remodeling","volume":"13","author":"Greenberg","year":"1996","journal-title":"Cardiology Review"},{"issue":"2","key":"10.1002\/14651858.CD012721.pub3-BIB0379|cit379","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S1388-9842(00)00060-X","article-title":"Improvement of cardiac output in patients with severe heart failure by use of ACE-inhibitors combined with the AT1-antagonist eprosartan","volume":"2","author":"Gremmler","year":"2000","journal-title":"European Journal of Heart Failure"},{"issue":"7","key":"10.1002\/14651858.CD012721.pub3-BIB0380|cit380","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/S0735-1097(00)01006-8","article-title":"Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure","volume":"36","author":"Groenning","year":"2000","journal-title":"Journal of the American College of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD012721.pub3-BIB0381|cit381","first-page":"58","article-title":"Antiremodeling effects on the left ventricle during beta-blockage with metaprolol in the treatment of chronic heart failure","volume":"7","author":"Groenning","year":"2001","journal-title":"Congestive Heart Failure"},{"issue":"5","key":"10.1002\/14651858.CD012721.pub3-BIB0382|cit382","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S1388-9842(02)00038-7","article-title":"Neurohumoral prediction of left-ventricular morphologic response to beta-blockade with metoprolol in chronic left-ventricular systolic heart failure","volume":"4","author":"Groenning","year":"2002","journal-title":"European Journal of Heart Failure"},{"issue":"6-7","key":"10.1002\/14651858.CD012721.pub3-BIB0383|cit383","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.ejheart.2007.02.007","article-title":"Pronounced improvement in systolic and diastolic ventricular long axis function after treatment with metoprolol","volume":"9","author":"Gruner Svealv","year":"2007","journal-title":"European Journal of Heart Failure"},{"issue":"2","key":"10.1002\/14651858.CD012721.pub3-BIB0384|cit384","first-page":"181","article-title":"A failed improvement in pulmonary function and exercise capacity with carvedilol in congestive heart failure despite an excellent effect on left ventricular function","volume":"43","author":"Guazzi","year":"1998","journal-title":"Cardiologia"},{"issue":"3 Pt 1","key":"10.1002\/14651858.CD012721.pub3-BIB0385|cit385","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S0002-8703(99)70148-1","article-title":"Pulmonary function, cardiac function, and exercise capacity in a follow-up of patients with congestive heart failure treated with carvedilol","volume":"138","author":"Guazzi","year":"1999","journal-title":"American Heart Journal"},{"issue":"2","key":"10.1002\/14651858.CD012721.pub3-BIB0386|cit386","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/0002-9149(92)91268-9","article-title":"Effects of captopril on left ventricular systolic and diastolic function after acute myocardial infarction","volume":"70","author":"G\u00f8tzsche","year":"1992","journal-title":"American Journal of Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD012721.pub3-BIB0387|cit387","first-page":"323","article-title":"The changes of PRA, ATII, ALD, ET and ANP in patients with left ventricular and intervention with enalapril","volume":"22","author":"Hanping","year":"1997","journal-title":"Bulletin of Hunan Medical University"},{"issue":"5","key":"10.1002\/14651858.CD012721.pub3-BIB0388|cit388","first-page":"365","article-title":"Effect of beta-blocker on left ventricular function and natriuretic peptides in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitor","volume":"64","author":"Hara","year":"2000","journal-title":"Circulation Journal \u2013 Official Journal of the Japanese Circulation Society"},{"issue":"10","key":"10.1002\/14651858.CD012721.pub3-BIB0389|cit389","first-page":"953","article-title":"Heart failure in coronary heart disease","volume":"34","author":"Hauf","year":"1993","journal-title":"Internist"},{"issue":"3","key":"10.1002\/14651858.CD012721.pub3-BIB0390|cit390","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.0742-2822.2004.03102.x","article-title":"Metoprolol CR\/XL improves systolic and diastolic left ventricular function in patients with chronic heart failure","volume":"21","author":"Hole","year":"2004","journal-title":"Echocardiography"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0391|cit391","first-page":"731","article-title":"Extended duration of aldosterone blockade fails to improve diastolic dysfunction over the effects of blood pressure in patients with heart failure and normal ejection fraction","volume":"31","author":"Holland","year":"2010","journal-title":"European Heart Journal"},{"issue":"4","key":"10.1002\/14651858.CD012721.pub3-BIB0392|cit392","first-page":"366","article-title":"Effects of perindopril on plasma soluble TRAIL and receptor soluble DR5 in patients with congestive heart failure","volume":"19","author":"Hong","year":"2003","journal-title":"Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi"},{"issue":"4","key":"10.1002\/14651858.CD012721.pub3-BIB0393|cit393","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s00392-007-0488-x","article-title":"Treatment of heart failure with ACE inhibitors and beta-blockers: what is next? AT1-receptor antagonists?","volume":"96","author":"Hoppe","year":"2007","journal-title":"Clinical Research in Cardiology"},{"issue":"2","key":"10.1002\/14651858.CD012721.pub3-BIB0394|cit394","first-page":"324","article-title":"Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial","volume":"147","author":"Hori","year":"2004","journal-title":"American Heart Journal"},{"issue":"22","key":"10.1002\/14651858.CD012721.pub3-BIB0395|cit395","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1016\/j.jacc.2010.06.044","article-title":"Longitudinal and circumferential strain rate, left ventricular remodeling, and prognosis after myocardial infarction","volume":"56","author":"Hung","year":"2010","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0396|cit396","unstructured":"Non-invasive cardiac imaging in the detection and assessment of subclinical diabetic heart disease www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=308109"},{"issue":"3","key":"10.1002\/14651858.CD012721.pub3-BIB0397|cit397","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ijcard.2011.07.051","article-title":"Improved insulin sensitivity by the angiotensin receptor antagonist irbesartan in patients with systolic heart failure: a randomized double-blinded placebo-controlled study","volume":"161","author":"Doehner","year":"2012","journal-title":"International Journal of Cardiology"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0398|cit398","unstructured":"Effect of irbesartan on insulin sensitivity in chronic heart failure clinicaltrials.gov\/ct2\/show\/NCT00347087"},{"issue":"1","key":"10.1002\/14651858.CD012721.pub3-BIB0399|cit399","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/hr.2011.169","article-title":"Adding thiazide to a renin-angiotensin blocker improves left ventricular relaxation and improves heart failure in patients with hypertension","volume":"35","author":"Ito","year":"2012","journal-title":"Hypertension Research"},{"issue":"3","key":"10.1002\/14651858.CD012721.pub3-BIB0400|cit400","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1365-2125.1991.tb05534.x","article-title":"A comparison of the chronic effect of oral xamoterol and enalapril on blood pressure and renal function in mild to moderate heart failure","volume":"31","author":"Jamieson","year":"1991","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0401|cit401","first-page":"776","article-title":"Biomarker and imaging responses to spironolactone in subclinical diabetic cardiomyopathy","volume":"15","author":"Jellis","year":"2014","journal-title":"European Heart Journal"},{"issue":"13","key":"10.1002\/14651858.CD012721.pub3-BIB0402|cit402","doi-asserted-by":"crossref","first-page":"E1076","DOI":"10.1016\/S0735-1097(12)61077-8","article-title":"Backscatter, T1 mapping or pro-collagen biomarkers for non-invasive assessment of treatment response to anti-fibrotic therapy in subclinical diabetic cardiomyopathy? A randomized trial","volume":"59","author":"Jellis","year":"2012","journal-title":"Journal of the American College of Cardiology"},{"issue":"14","key":"10.1002\/14651858.CD012721.pub3-BIB0403|cit403","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1056\/NEJMe030030","article-title":"Aldosterone blockade and heart failure","volume":"348","author":"Jessup","year":"2003","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0404|cit404","doi-asserted-by":"crossref","first-page":"c4202","DOI":"10.1136\/bmj.c4202","article-title":"Should treatment for heart failure with preserved ejection fraction differ from that for heart failure with reduced ejection fraction?","volume":"341","author":"Jong","year":"2010","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0405|cit405","unstructured":"J-TASTE trial rctportal.niph.go.jp\/en\/detail?trial_id=jRCTs051180137"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0406|cit406","unstructured":"The multicenter study for effects of eplerenone on cardiac diastolic dysfunction in hypertensive patients www.who.int\/trialsearch\/Trial2.aspx?TrialID=JPRN-UMIN000006415"},{"issue":"3","key":"10.1002\/14651858.CD012721.pub3-BIB0407|cit407","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10557-008-6081-3","article-title":"Electrophysiological effects of carvedilol administration in patients with dilated cardiomyopathy","volume":"22","author":"Kanoupakis","year":"2008","journal-title":"Cardiovascular Drugs and Therapy"},{"issue":"1","key":"10.1002\/14651858.CD012721.pub3-BIB0408|cit408","first-page":"79","article-title":"Diastolic dysfunction","volume":"51","author":"Kapel'ko","year":"2011","journal-title":"Kardiologiia"},{"issue":"12","key":"10.1002\/14651858.CD012721.pub3-BIB0409|cit409","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.2967\/jnumed.107.045427","article-title":"Additive effects of spironolactone and candesartan on cardiac sympathetic nerve activity and left ventricular remodeling in patients with congestive heart failure","volume":"48","author":"Kasama","year":"2007","journal-title":"Journal of Nuclear Medicine"},{"issue":"4-5","key":"10.1002\/14651858.CD012721.pub3-BIB0410|cit410","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1159\/000175805","article-title":"Left ventricular filling dynamics by Doppler echocardiography in dilated cardiomyopathy: one-year follow-up in patients treated with captopril compared to placebo","volume":"81","author":"Keren","year":"1992","journal-title":"Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD012721.pub3-BIB0411|cit411","first-page":"90","article-title":"One-year clinical and echocardiographic follow-up of patients with congestive cardiomyopathy treated with captopril compared to placebo","volume":"30","author":"Keren","year":"1994","journal-title":"Israel Journal of Medical Sciences"},{"issue":"6","key":"10.1002\/14651858.CD012721.pub3-BIB0412|cit412","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1136\/eb-2013-101238","article-title":"Lack of definitive evidence for the use of renin-angiotensin system antagonists for heart failure with preserved ejection fraction","volume":"18","author":"Khalid","year":"2013","journal-title":"Evidence Based Medicine"},{"issue":"3","key":"10.1002\/14651858.CD012721.pub3-BIB0413|cit413","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000368746","article-title":"The effect of carvedilol on B-type natriuretic peptide and cardiac function in patients with heart failure and persistent atrial fibrillation","volume":"130","author":"Khand","year":"2015","journal-title":"Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD012721.pub3-BIB0414|cit414","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1097\/HJH.0000000000000874","article-title":"Impact of left ventricular ejection function on blood pressure-lower ing therapy in hypertensive patients with coronary artery disease","volume":"34","author":"Kikuchi","year":"2016","journal-title":"Journal of Hypertension"},{"issue":"2","key":"10.1002\/14651858.CD012721.pub3-BIB0415|cit415","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jjcc.2010.11.006","article-title":"Effects of mineralocorticoid receptor antagonist spironolactone on atrial conduction and remodeling in patients with heart failure","volume":"57","author":"Kimura","year":"2011","journal-title":"Journal of Cardiology"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD012721.pub3-BIB0416|cit416","first-page":"465","article-title":"Diabetic heart disease","volume":"65","author":"Kinugawa","year":"2007","journal-title":"Nippon Rinsho"},{"issue":"9","key":"10.1002\/14651858.CD012721.pub3-BIB0417|cit417","doi-asserted-by":"crossref","first-page":"962; author rep","DOI":"10.1016\/j.ejheart.2007.06.006","article-title":"Prescription of beta-blockers in patients with advanced heart failure and preserved left ventricular ejection fraction. Clinical implications and survival","volume":"9","author":"Kjekshus","year":"2007","journal-title":"European Journal of Heart Failure"},{"issue":"4","key":"10.1002\/14651858.CD012721.pub3-BIB0418|cit418","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/14017439850140012","article-title":"The Angiotensin Converting Enzyme Inhibition Post Revascularization Study (APRES). Effects of ramipril in patients with reduced left ventricular function. Rationale, design, methods, baseline characteristics and first-year experience","volume":"32","author":"Kj\u00f8ller-Hansen","year":"1998","journal-title":"Scandinavian Cardiovascular Journal"},{"issue":"Spec No 1","key":"10.1002\/14651858.CD012721.pub3-BIB0419|cit419","first-page":"283","article-title":"Prognosis of mild chronic heart failure: effects of the ACE inhibitor captopril","volume":"16","author":"Kleber","year":"1991","journal-title":"Herz"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD012721.pub3-BIB0420|cit420","first-page":"111","article-title":"Development of heart failure after myocardial infarct: changes in plasma renin activity, angiotensin II, catecholamines and atrial natriuretic peptide","volume":"80","author":"Kleber","year":"1991","journal-title":"Zeitschrift f\u00fcr Kardiologie"},{"issue":"11","key":"10.1002\/14651858.CD012721.pub3-BIB0421|cit421","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/clc.4960211105","article-title":"Treatment with ramipril improves systolic function even in patients with mild systolic dysfunction and symptoms of heart failure after acute myocardial infarction","volume":"21","author":"Kongstad-Rasmussen","year":"1998","journal-title":"Clinical Cardiology"},{"issue":"2","key":"10.1002\/14651858.CD012721.pub3-BIB0422|cit422","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0002-8703(96)90363-4","article-title":"Changes in plasma endothelin-1 levels reflect clinical response to beta-blockade in chronic heart failure","volume":"131","author":"Krum","year":"1996","journal-title":"American Heart Journal"},{"issue":"10","key":"10.1002\/14651858.CD012721.pub3-BIB0423|cit423","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/ejhf.408","article-title":"The Aliskiren Trial to Minimize OutcomeS in Patients with HEart failure trial (ATMOSPHERE): revised statistical analysis plan and baseline characteristics","volume":"17","author":"Krum","year":"2015","journal-title":"European Journal of Heart Failure"},{"issue":"10","key":"10.1002\/14651858.CD012721.pub3-BIB0424|cit424","first-page":"646","article-title":"Clinical study of the month. The CHARM study","volume":"58","author":"Kulbertus","year":"2003","journal-title":"Revue Medicale de Liege"},{"issue":"6","key":"10.1002\/14651858.CD012721.pub3-BIB0425|cit425","first-page":"1+14","article-title":"Blocking aldosterone reduces deaths in post-MI heart failure","volume":"20","author":"Kuznar","year":"2003","journal-title":"Cardiology Review"},{"issue":"1-2","key":"10.1002\/14651858.CD012721.pub3-BIB0426|cit426","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/BF00192352","article-title":"Effects of lisinopril on congestive heart failure in normotensive patients with diastolic dysfunction but intact systolic function","volume":"49","author":"Lang","year":"1995","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"6","key":"10.1002\/14651858.CD012721.pub3-BIB0427|cit427","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s002280050137","article-title":"Adaptive changes in the acute haemodynamic effects of cilazapril during chronic treatment. Comparison with long-term clinical effect","volume":"50","author":"Larsen","year":"1996","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"Spec No 1","key":"10.1002\/14651858.CD012721.pub3-BIB0428|cit428","first-page":"73","article-title":"Contribution of perindopril to the treatment of chronic congestive cardiac insufficiency. Multicenter pilot double blind study versus placebo","volume":"82","author":"Bounhoure","year":"1989","journal-title":"Archives des Maladies du Coeur et des Vaisseaux"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012721.pub3-BIB0429|cit429","first-page":"575","article-title":"Value of perindopril in the treatment of chronic congestive heart failure. Multicenter double-blind placebo-controlled study","volume":"11","author":"Bounhoure","year":"1989","journal-title":"Clinical and experimental hypertension. Part A, Theory and practice"},{"issue":"Spec Iss IV","key":"10.1002\/14651858.CD012721.pub3-BIB0430|cit430","first-page":"89","article-title":"Perindopril and chronic cardia failure","volume":"84","author":"Bounhoure","year":"1991","journal-title":"Archives des Maladies du Coeur et des Vaisseaux"},{"issue":"3 II Suppl","key":"10.1002\/14651858.CD012721.pub3-BIB0431|cit431","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/0002-8703(93)90933-Z","article-title":"Efficacy and acceptability of perindopril in mild to moderate chronic congestive heart failure","volume":"126","author":"Lechat","year":"1993","journal-title":"American Heart Journal"},{"issue":"3","key":"10.1002\/14651858.CD012721.pub3-BIB0432|cit432","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0167-4943(99)00040-0","article-title":"Carvedilol in elderly patients with chronic heart failure, a 12 weeks randomized, placebo controlled open trial","volume":"29","author":"Leonetti Luparini","year":"1999","journal-title":"Archives of Gerontology and Geriatrics"},{"issue":"3B","key":"10.1002\/14651858.CD012721.pub3-BIB0433|cit433","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/0002-9343(88)90351-8","article-title":"Lisinopril versus placebo in older congestive heart failure patients","volume":"85","author":"Lewis","year":"1988","journal-title":"American Journal of Medicine"},{"issue":"35","key":"10.1002\/14651858.CD012721.pub3-BIB0434|cit434","first-page":"28","article-title":"Ventricular remodeling and cardiovascular events in patients with chronic heart failure and the interventional effects of metoprolol","volume":"9","author":"Li","year":"2005","journal-title":"Chinese Journal of Clinical Rehabilitation"},{"issue":"1","key":"10.1002\/14651858.CD012721.pub3-BIB0435|cit435","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1520-037X.2004.02879.x","article-title":"VALIANT and EUROPA","volume":"7","author":"Liebson","year":"2004","journal-title":"Preventive Cardiology"},{"issue":"7","key":"10.1002\/14651858.CD012721.pub3-BIB0436|cit436","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1016\/S0735-1097(01)01641-2","article-title":"Aspirin impairs reverse myocardial remodeling in patients with heart failure treated with beta-blockers","volume":"38","author":"Lindenfeld","year":"2001","journal-title":"JACC"},{"issue":"9157","key":"10.1002\/14651858.CD012721.pub3-BIB0437|cit437","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(99)00050-1","article-title":"Beta-blockers in heart failure","volume":"353","author":"Lindsay","year":"1999","journal-title":"Lancet"},{"issue":"8","key":"10.1002\/14651858.CD012721.pub3-BIB0438|cit438","first-page":"567","article-title":"Effects of spironolactone in treatment of elderly hypertensive patients with diastolic heart failure","volume":"25","author":"Liu","year":"2006","journal-title":"Chinese Journal of New Drugs and Clinical Remedies"},{"issue":"1","key":"10.1002\/14651858.CD012721.pub3-BIB0439|cit439","first-page":"7","article-title":"Analysis of therapeutic effect and safety of target-dose metoprolol in the treatment of patients with diabetes mellitus with chronic heart failure","volume":"30","author":"Liu","year":"2014","journal-title":"Pakistan Journal of Medical Sciences"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0440|cit440","first-page":"23","article-title":"Diastolic heart failure","volume":"147","author":"Logeart","year":"2006","journal-title":"Archives des Maladies du Coeur et des Vaisseaux - Pratique"},{"issue":"4","key":"10.1002\/14651858.CD012721.pub3-BIB0441|cit441","first-page":"281","article-title":"Spironolactone in heart failure","volume":"25","author":"Lopez Herrero","year":"2000","journal-title":"Atenci\u00f3n Primaria"},{"issue":"12","key":"10.1002\/14651858.CD012721.pub3-BIB0442|cit442","doi-asserted-by":"crossref","first-page":"2363; author re","DOI":"10.1253\/circj.CJ-09-73-1201","article-title":"Re: Effect of carvedilol on plasma adiponectin concentration in patients with chronic heart failure","volume":"73","author":"Lou","year":"2009","journal-title":"Circulation Journal"},{"issue":"19","key":"10.1002\/14651858.CD012721.pub3-BIB0443|cit443","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1097\/00029330-200710010-00016","article-title":"Effects of metoprolol on beta1 adrenergic receptor polymorphism and receptor density in urban Chinese patients with heart failure","volume":"120","author":"Luo","year":"2007","journal-title":"Chinese Medical Journal"},{"issue":"47","key":"10.1002\/14651858.CD012721.pub3-BIB0444|cit444","first-page":"22","article-title":"Effect of valsartan and hydrochloric benazepril on ventricular remodeling and cardiac function of patients with heart failure","volume":"9","author":"Ma","year":"2005","journal-title":"Journal of Clinical Rehabilitative Tissue Engineering Research"},{"issue":"1","key":"10.1002\/14651858.CD012721.pub3-BIB0445|cit445","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1751-7133.2008.00038.x","article-title":"Carvedilol produces sustained long-term benefits: follow-up at 12 years","volume":"15","author":"MacGregor","year":"2009","journal-title":"Congestive Heart Failure"},{"issue":"Suppl 12","key":"10.1002\/14651858.CD012721.pub3-BIB0446|cit446","first-page":"S398","article-title":"The effects of low dose eplerenone on markers of collagen turnover in diastolic heart failure","volume":"177","author":"Mak","year":"2008","journal-title":"Irish Journal of Medical Science"},{"issue":"9591","key":"10.1002\/14651858.CD012721.pub3-BIB0447|cit447","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S0140-6736(07)61434-2","article-title":"The VALIDD study","volume":"370","author":"Malnick","year":"2007","journal-title":"Lancet"},{"issue":"Suppl 22","key":"10.1002\/14651858.CD012721.pub3-BIB0448|cit448","first-page":"Abstract 16910","article-title":"Abstract 16910: can spironolactone mitigate myocardial fibrosis and alter sudden death risk and heart failure symptoms in patients with hypertrophic cardiomyopathy?: a prospective, randomized trial","volume":"128","author":"Maron","year":"2013","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0449|cit449","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.amjmed.2018.02.025","article-title":"Effect of spironolactone on myocardial fibrosis and other clinical variables in patients with hypertrophic cardiomyopathy","volume":"131","author":"Maron","year":"2018","journal-title":"American Journal of Medicine"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0450|cit450","unstructured":"Clinical and therapeutic implications of fibrosis in hypertrophic cardiomyopathy clinicaltrials.gov\/ct2\/show\/NCT00879060"},{"issue":"3","key":"10.1002\/14651858.CD012721.pub3-BIB0451|cit451","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0167-5273(98)00149-1","article-title":"Valsartan in heart failure patients previously untreated with an ACE inhibitor","volume":"65","author":"Mazayev","year":"1998","journal-title":"International Journal of Cardiology"},{"issue":"9","key":"10.1002\/14651858.CD012721.pub3-BIB0452|cit452","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJM200402263500918","article-title":"Valsartan, captopril, or both in myocardial infarction","volume":"350","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD012721.pub3-BIB0453|cit453","first-page":"550","article-title":"Mineralocorticoid receptor antagonists and mortality in heart failure with concurrent atrial fibrillation","volume":"5","author":"McCullough","year":"2012","journal-title":"Circulation"},{"issue":"7","key":"10.1002\/14651858.CD012721.pub3-BIB0454|cit454","first-page":"282","article-title":"HCQIP Project Report--findings released in Use of Ace Inhibitors in Heart Failure Project","volume":"38","author":"McIlwain","year":"1997","journal-title":"Journal of the Mississippi State Medical Association"},{"issue":"2","key":"10.1002\/14651858.CD012721.pub3-BIB0455|cit455","first-page":"182","article-title":"Heart failure","volume":"86","author":"McKelvie","year":"2012","journal-title":"American Family Physician"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0456|cit456","doi-asserted-by":"crossref","first-page":"i42","DOI":"10.1136\/heart.84.suppl_1.i42","article-title":"AT(1) receptor antagonists-beyond blood pressure control: possible place in heart failure treatment","volume":"84 Suppl 1","author":"McMurray","year":"2000","journal-title":"Heart"},{"issue":"20","key":"10.1002\/14651858.CD012721.pub3-BIB0457|cit457","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1161\/01.CIR.0000147274.83071.68","article-title":"Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?","volume":"110","author":"McMurray","year":"2004","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0458|cit458","first-page":"S173","article-title":"The impact of the rapid use of beta blockers on ventricular mortality and remodeling in and-stage heart failure","volume":"10","author":"Melo","year":"2011","journal-title":"European Journal of Heart Failure. Supplement"},{"issue":"19","key":"10.1002\/14651858.CD012721.pub3-BIB0459|cit459","first-page":"e754","article-title":"The impact of the rapid use of beta-blockers on ventricular remodeling and mortality in end-stage heart failure (the FAST study)","volume":"125","author":"Melo","year":"2012","journal-title":"Circulation"},{"issue":"5","key":"10.1002\/14651858.CD012721.pub3-BIB0460|cit460","first-page":"358","article-title":"Effect of Nebivolol on MIBG Parameters and Exercise in Heart Failure with Normal Ejection Fraction","volume":"106","author":"Messias L","year":"2016","journal-title":"Arquivos Brasileiros de Cardiologia"},{"issue":"5","key":"10.1002\/14651858.CD012721.pub3-BIB0461|cit461","first-page":"346","article-title":"Diastolic dysfunction in heart failure with CHARMES (candesartan in heart failure assessment of reduction in mortality and morbidity) preserved systolic function: Results of the CHARM echocardiographic sub-study","volume":"3","author":"Meuleman","year":"2007","journal-title":"Medecine Therapeutique - Cardio"},{"issue":"13","key":"10.1002\/14651858.CD012721.pub3-BIB0462|cit462","first-page":"48","article-title":"Conclusions from CHARM interview with Prof. Veselin Mitrovich, Bad Nauheim. Strong evidence: more help for weak hearts","volume":"147","author":"Mitrovic","year":"2005","journal-title":"MMW Fortschritte der Medizin"},{"issue":"4","key":"10.1002\/14651858.CD012721.pub3-BIB0463|cit463","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1023\/B:CARD.0000041250.00079.84","article-title":"JIKEI HEART Study--a morbi-mortality and remodeling study with valsartan in Japanese patients with hypertension and cardiovascular disease","volume":"18","author":"Mochizuki","year":"2004","journal-title":"Cardiovascular Drugs and Therapy"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0464|cit464","first-page":"A562","article-title":"A randomized, double-blind, placebo-controlled trial of spironolactone on diastolic dysfunction in diabetic patients","volume":"60","author":"Morales","year":"2011","journal-title":"Diabetes"},{"issue":"5","key":"10.1002\/14651858.CD012721.pub3-BIB0465|cit465","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1067\/mhj.2001.114802","article-title":"ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects","volume":"141","author":"Murdoch","year":"2001","journal-title":"American Heart Journal"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0466|cit466","unstructured":"Reversing endothelial and diastolic dysfunction and improving collagen turnover in diastolic heart failure (PREDICT) clinicaltrials.gov\/show\/NCT00293150"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0467|cit467","unstructured":"Aldosterone blockade in heart failure (ARCTIC-D) clinicaltrials.gov\/show\/NCT00523757"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0468|cit468","unstructured":"A trial of fimasartan for early diastolic heart failure (FINE) clinicaltrials.gov\/show\/NCT01691118"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0469|cit469","unstructured":"Impacts of aldosterone blockade on myocardial remodeling in hypertensive patients with diastolic failing heart clinicaltrials.gov\/ct2\/show\/NCT01944384"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0470|cit470","unstructured":"Metoprolol XR in heart failure with normal ejection fraction (HFNEF) clinicaltrials.gov\/ct2\/show\/NCT03882710"},{"issue":"5","key":"10.1002\/14651858.CD012721.pub3-BIB0471|cit471","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S1388-9842(03)00054-0","article-title":"Beta-blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs. nebivolol","volume":"5","author":"Nodari","year":"2003","journal-title":"European Journal of Heart Failure"},{"issue":"2","key":"10.1002\/14651858.CD012721.pub3-BIB0472|cit472","first-page":"111","article-title":"Spironolactone in patients with heart failure and preserved ejection fraction","volume":"216","author":"Nunez","year":"2016","journal-title":"Revista Clinica Espanola"},{"issue":"2","key":"10.1002\/14651858.CD012721.pub3-BIB0473|cit473","first-page":"48,50","article-title":"ACE inhibitors in the management and prevention of heart failure","volume":"88","author":"O'Callaghan","year":"1995","journal-title":"Irish Medical Journal"},{"issue":"6","key":"10.1002\/14651858.CD012721.pub3-BIB0474|cit474","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1463-1326.2007.00730.x","article-title":"Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS","volume":"10","author":"O'Keefe","year":"2008","journal-title":"Diabetes Obesity and Metabolism"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0475|cit475","doi-asserted-by":"crossref","unstructured":"Sharma N Lye M Does stopping diuretics prevent first dose hypotension in older heart failure patients commencing ACE inhibitor therapy? European Geriatric Medicine 2015 6 4 366 7","DOI":"10.1016\/j.eurger.2015.02.013"},{"issue":"5","key":"10.1002\/14651858.CD012721.pub3-BIB0476|cit476","first-page":"586","article-title":"Mineralocorticoid receptor antagonists and cardiovascular mortality in patients with atrial fibrillation and left ventricular dysfunction: insights from the Atrial Fibrillation and Congestive Heart Failure Trial","volume":"5","author":"O'Meara","year":"2012","journal-title":"Circulation"},{"issue":"7","key":"10.1002\/14651858.CD012721.pub3-BIB0477|cit477","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1517\/14656566.5.7.1589","article-title":"Candesartan for the treatment of hypertension and heart failure","volume":"5","author":"Ostergren","year":"2004","journal-title":"Expert Opinion in Pharmacotherapy"},{"issue":"6","key":"10.1002\/14651858.CD012721.pub3-BIB0478|cit478","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/01.fjc.0000159880.12067.34","article-title":"Left ventricular diastolic function improvement by carvedilol therapy in advanced heart failure","volume":"45","author":"Palazzuoli","year":"2005","journal-title":"Journal of Cardiovascular Pharmacology"},{"issue":"1","key":"10.1002\/14651858.CD012721.pub3-BIB0479|cit479","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0002-8703(92)90753-I","article-title":"Metabolic and cardiovascular benefits deriving from beta-adrenergic blockade in chronic congestive heart failure","volume":"123","author":"Paolisso","year":"1992","journal-title":"American Heart Journal"},{"issue":"5","key":"10.1002\/14651858.CD012721.pub3-BIB0480|cit480","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.echo.2005.12.022","article-title":"The effect of carvedilol therapy on myocardial functional reserve in patients with advanced heart failure caused by nonischemic dilated cardiomyopathy","volume":"19","author":"Paraskevaidis","year":"2006","journal-title":"Journal of the American Society of Echocardiography"},{"issue":"1","key":"10.1002\/14651858.CD012721.pub3-BIB0481|cit481","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1186\/s13063-016-1656-y","article-title":"Comparative effects of nebivolol and carvedilol on left ventricular diastolic function in older heart failure patients with preserved ejection fraction: study protocol for a randomized controlled trial","volume":"17","author":"Park","year":"2016","journal-title":"Trials"},{"issue":"1","key":"10.1002\/14651858.CD012721.pub3-BIB0482|cit482","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0002-8703(97)70104-2","article-title":"Acute and long-term effects of the angiotensin-converting enzyme inhibitor, enalapril, on adrenergic activity and sensitivity during exercise in patients with left ventricular systolic dysfunction","volume":"134","author":"Patten","year":"1997","journal-title":"American Heart Journal"},{"issue":"3","key":"10.1002\/14651858.CD012721.pub3-BIB0483|cit483","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0167-5273(99)00198-9","article-title":"The carvedilol hibernation reversible ischaemia trial, marker of success (CHRISTMAS) study. Methodology of a randomised, placebo controlled, multicentre study of carvedilol in hibernation and heart failure","volume":"72","author":"Pennell","year":"2000","journal-title":"International Journal of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD012721.pub3-BIB0484|cit484","first-page":"57","article-title":"Clinical study of the month. Effects of valsartan in chronic heart failure: the VAL-HeFT study","volume":"57","author":"Pierard","year":"2002","journal-title":"Revue Medical de Liege"},{"issue":"3","key":"10.1002\/14651858.CD012721.pub3-BIB0485|cit485","first-page":"159","article-title":"Valsartan in acute myocardial infarction trial","volume":"6","author":"Pina","year":"2004","journal-title":"Current Cardiology Reports"},{"issue":"3","key":"10.1002\/14651858.CD012721.pub3-BIB0486|cit486","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jacc.2005.04.038","article-title":"Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure","volume":"46","author":"Pitt","year":"2005","journal-title":"JACC"},{"issue":"16","key":"10.1002\/14651858.CD012721.pub3-BIB0487|cit487","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.108.778811","article-title":"Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS)","volume":"118","author":"Pitt","year":"2008","journal-title":"Circulation"},{"issue":"7","key":"10.1002\/14651858.CD012721.pub3-BIB0488|cit488","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/eurjhf\/hfr034","article-title":"Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment study","volume":"13","author":"Pitt","year":"2011","journal-title":"European Journal of Heart Failure"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0489|cit489","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.ijcard.2015.02.056","article-title":"Heart rate control in patients with left ventricular systolic dysfunction and heart failure","volume":"184","author":"Pourdjabbar","year":"2015","journal-title":"International Journal of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD012721.pub3-BIB0490|cit490","first-page":"A46","article-title":"Targeted heart rate reduction using carvedilol ivabradine improves left ventricular diastolic dysfunction,clinical progression and survival in cirrhosis","volume":"35","author":"Premkumar","year":"2016","journal-title":"Indian Journal of Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD012721.pub3-BIB0491|cit491","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0002-9149(97)00874-6","article-title":"Effects of carvedilol on right ventricular function in chronic heart failure","volume":"81","author":"Quaife","year":"1998","journal-title":"American Journal of Cardiology"},{"issue":"3","key":"10.1002\/14651858.CD012721.pub3-BIB0492|cit492","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1023\/B:CEPR.0000012388.85901.1c","article-title":"Beta blockers improve outcome in patients with heart failure and atrial fibrillation: U.S. carvedilol study","volume":"7","author":"Ramaswamy","year":"2003","journal-title":"Cardiac Electrophysiology Review"},{"issue":"1","key":"10.1002\/14651858.CD012721.pub3-BIB0493|cit493","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1023\/A:1011166919718","article-title":"The Carvedilol and ACE-Inhibitor Remodelling Mild Heart Failure EvaluatioN trial (CARMEN)--rationale and design","volume":"15","author":"Remme","year":"2001","journal-title":"Cardiovascular Drugs and Therapy"},{"issue":"1","key":"10.1002\/14651858.CD012721.pub3-BIB0494|cit494","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1023\/B:CARD.0000025756.32499.6f","article-title":"The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN)","volume":"18","author":"Remme","year":"2004","journal-title":"Cardiovascular Drugs and Therapy"},{"issue":"1","key":"10.1002\/14651858.CD012721.pub3-BIB0495|cit495","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.hfc.2004.12.001","article-title":"Could beta-blockers precede or replace angiotensin-converting enzyme inhibitors in heart failure?","volume":"1","author":"Remme","year":"2005","journal-title":"Heart Failure Clinic"},{"issue":"733","key":"10.1002\/14651858.CD012721.pub3-BIB0496|cit496","first-page":"58","article-title":"Captopril in the early phase of cardiac failure: effects on left ventricular diastolic function","volume":"228","author":"Rimatori","year":"1990","journal-title":"Journal of International Medicine Supplement"},{"issue":"10","key":"10.1002\/14651858.CD012721.pub3-BIB0497|cit497","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/clc.4960281008","article-title":"Spironolactone improves diastolic function in the elderly","volume":"28","author":"Roongsritong","year":"2005","journal-title":"Clinical Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD012721.pub3-BIB0498|cit498","first-page":"A81","article-title":"Effect of aliskiren and antihypertensive drugs on diastolic function in hypertensives with diastolic dysfunction: A randomised study","volume":"13","author":"Rosa","year":"2011","journal-title":"Journal of Clinical Hypertension"},{"issue":"4","key":"10.1002\/14651858.CD012721.pub3-BIB0499|cit499","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00108-003-0874-z","article-title":"Hemodynamic effects of the beta blocker nebivolol","volume":"44","author":"Rosenkranz","year":"2003","journal-title":"Internist"},{"issue":"19","key":"10.1002\/14651858.CD012721.pub3-BIB0500|cit500","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1016\/j.jacc.2011.04.049","article-title":"Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects: Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy","volume":"58","author":"Rossignol","year":"2011","journal-title":"JACC"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0501|cit501","first-page":"787","article-title":"Effects of aliskiren on Left ventricular remodeling in patients with dilated cardiomyopathy","volume":"32","author":"Sakai","year":"2011","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0502|cit502","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1136\/hrt.79.1.86","article-title":"Beta blockers in heart failure: a comparison of a vasodilating beta blocker with metoprolol","volume":"79","author":"Sanderson","year":"1998","journal-title":"Heart"},{"issue":"7658","key":"10.1002\/14651858.CD012721.pub3-BIB0503|cit503","first-page":"727","article-title":"Keep patients with heart failure out of hospital: Ensure they get target doses","volume":"286","author":"Sanghera","year":"2011","journal-title":"Pharmaceutical Journal"},{"issue":"4","key":"10.1002\/14651858.CD012721.pub3-BIB0504|cit504","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1001\/jamainternmed.2014.8009","article-title":"beta-Blockers in diabetic patients with heart failure","volume":"175","author":"Santulli","year":"2015","journal-title":"JAMA Internal Medicine"},{"issue":"3","key":"10.1002\/14651858.CD012721.pub3-BIB0505|cit505","first-page":"124","article-title":"Treatment of mild-to-moderate congestive heart failure with the angiotensin converting enzyme inhibitor quinapril","volume":"8","author":"Sardu","year":"1991","journal-title":"Advances in Therapy"},{"issue":"5","key":"10.1002\/14651858.CD012721.pub3-BIB0506|cit506","first-page":"195","article-title":"Angiotensin receptor antagonists: No advantage for hypertensive patients with diastolic dysfunction","volume":"31","author":"Schindler","year":"2008","journal-title":"Medizinische Monatsschrift fur Pharmazeuten"},{"issue":"23","key":"10.1002\/14651858.CD012721.pub3-BIB0507|cit507","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/BF03365781","article-title":"Hypertension and diastolic dysfunction","volume":"151","author":"Schwab","year":"2009","journal-title":"MMW Fortschritte der Medizin"},{"issue":"7","key":"10.1002\/14651858.CD012721.pub3-BIB0508|cit508","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1157\/13123994","article-title":"Summary of the clinical studies reported in the 57th Scientific Session of the American College of Cardiology (Chicago, USA, 30 march-2 april 2008)","volume":"61","author":"Segovia","year":"2008","journal-title":"Revista Espanola de Cardiologia"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0509|cit509","first-page":"531","article-title":"The Carvedilol and ACE-Inhibitor Remodelling Mild Heart Failure Evaluation Trial","volume":"65 Suppl 4","author":"Shimamoto","year":"2007","journal-title":"Nippon Rinsho"},{"issue":"3","key":"10.1002\/14651858.CD012721.pub3-BIB0510|cit510","first-page":"85","article-title":"Controlled release metoprolol succinate in MERIT-HF. Analysis of patients subgroups","volume":"48","author":"Sidorenko","year":"2008","journal-title":"Kardiologiia"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0511|cit511","doi-asserted-by":"crossref","first-page":"P311","DOI":"10.1186\/1532-429X-16-S1-P311","article-title":"Progression of myocardial fibrosis by magnetic resonance imaging in patients with duchenne and becker muscular dystrophy and preserved left ventricular ejection fraction-a randomized clinical trial for treatment with ACE inhibitors","volume":"16","author":"Silva","year":"2014","journal-title":"Journal of Cardiovascular Magnetic Resonance"},{"issue":"41","key":"10.1002\/14651858.CD012721.pub3-BIB0512|cit512","first-page":"1829","article-title":"Congestive heart failure, part 2: treatment","volume":"109","author":"Smith","year":"2012","journal-title":"Lakartidningen"},{"issue":"5","key":"10.1002\/14651858.CD012721.pub3-BIB0513|cit513","first-page":"355","article-title":"Diastolic cardiac insufficiency","volume":"153","author":"Spoto","year":"2002","journal-title":"La Clinica Terapeutica"},{"issue":"5","key":"10.1002\/14651858.CD012721.pub3-BIB0514|cit514","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1161\/CIRCULATIONAHA.105.557173","article-title":"Letter regarding article by Weintraub et al, \"Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure\"","volume":"112","author":"Stecker","year":"2005","journal-title":"Circulation"},{"issue":"3","key":"10.1002\/14651858.CD012721.pub3-BIB0515|cit515","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00108-005-1572-9","article-title":"New study results in cardiology","volume":"47","author":"Stiefelhagen","year":"2006","journal-title":"Internist"},{"issue":"4","key":"10.1002\/14651858.CD012721.pub3-BIB0516|cit516","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s11897-004-0005-8","article-title":"Aldosterone in heart failure: pathophysiology and treatment","volume":"1","author":"Struthers","year":"2004","journal-title":"Current Heart Failure Reports"},{"issue":"9","key":"10.1002\/14651858.CD012721.pub3-BIB0517|cit517","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1093\/oxfordjournals.eurheartj.a015063","article-title":"The value of angiotensin converting enzyme inhibitors for the treatment of patients with left ventricular dysfunction, heart failure or after acute myocardial infarction","volume":"17","author":"Swedberg","year":"1996","journal-title":"European Heart Journal"},{"issue":"3","key":"10.1002\/14651858.CD012721.pub3-BIB0518|cit518","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1177\/204748739900600301","article-title":"Beta-blockers and heart failure","volume":"6","author":"Swedberg","year":"1999","journal-title":"Journal of Cardiovascular Risk"},{"issue":"4","key":"10.1002\/14651858.CD012721.pub3-BIB0519|cit519","first-page":"273","article-title":"Beneficial effects of enalapril on the diastolic ventricular function in Chagas myocardiopathy","volume":"60","author":"Szajnbok","year":"1993","journal-title":"Arquivos Brasileiros de Cardiologia"},{"issue":"23","key":"10.1002\/14651858.CD012721.pub3-BIB0520|cit520","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1136\/hrt.2009.179952","article-title":"Therapeutic options for systemic right ventricular failure","volume":"95","author":"Szymanski","year":"2009","journal-title":"Heart"},{"issue":"3","key":"10.1002\/14651858.CD012721.pub3-BIB0521|cit521","first-page":"392","article-title":"Spironolactone in chronic hemodialysis patients improves cardiac function","volume":"20","author":"Taheri","year":"2009","journal-title":"Saudi Journal of Kidney Diseases and Transplantation"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0522|cit522","first-page":"478","article-title":"Hypertension in patients with heart failure","volume":"62 Suppl 3","author":"Takekoshi","year":"2004","journal-title":"Nippon Rinsho"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0523|cit523","first-page":"S114","article-title":"Relation of loop diuretic dose to morbimortality in patients with heart failure and left ventricular systolic dysfunction: Insights from EPHESUS","volume":"10","author":"Tala","year":"2011","journal-title":"European Journal of Heart Failure. Supplement"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0524|cit524","first-page":"2","article-title":"Relation of loop diuretic dose to morbimortality in patients with heart failure and left ventricular systolic dysfunction: Insights from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS)","volume":"25","author":"Tala","year":"2011","journal-title":"Fundamental and Clinical Pharmacology"},{"issue":"2","key":"10.1002\/14651858.CD012721.pub3-BIB0525|cit525","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ijcard.2012.08.054","article-title":"Cardiac functional benefits of ivabradine therapy in patients with severe heart failure","volume":"165","author":"Tan","year":"2013","journal-title":"International Journal of Cardiology"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0526|cit526","first-page":"524","article-title":"Cardioprotective effect of aldosterone antagonists for ventricular remodeling","volume":"64 Suppl 5","author":"Tatsumi","year":"2006","journal-title":"Nippon Rinsho"},{"issue":"5 Suppl Nitric","key":"10.1002\/14651858.CD012721.pub3-BIB0527|cit527","doi-asserted-by":"crossref","first-page":"S216","DOI":"10.1054\/S1071-9164(03)00591-8","article-title":"The African-American Heart Failure Trial (A-HeFT): rationale and methodology.[Erratum appears in J Card Fail. 2003 Dec;9(6):481 Note: Dosage error in article text]","volume":"9","author":"Taylor","year":"2003","journal-title":"Journal of Cardiac Failure"},{"issue":"3","key":"10.1002\/14651858.CD012721.pub3-BIB0528|cit528","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1054\/jcaf.2003.46","article-title":"Late breaking heart failure trials from the 2003 ACC meeting: EPHESUS and COMPANION","volume":"9","author":"Teerlink","year":"2003","journal-title":"Journal of Cardiac Failure"},{"issue":"6","key":"10.1002\/14651858.CD012721.pub3-BIB0529|cit529","first-page":"19","article-title":"The use of esmolol in patients with myocardial infarction complicated with acute left ventricular failure","volume":"45","author":"Tereshchenko","year":"2005","journal-title":"Kardiologiia"},{"issue":"7","key":"10.1002\/14651858.CD012721.pub3-BIB0530|cit530","doi-asserted-by":"crossref","first-page":"1333; author re","DOI":"10.1016\/j.jacc.2004.01.005","article-title":"Angiotensin-converting enzyme inhibitors, beta-blockers, and mortality in systolic heart failure","volume":"43","author":"Thornton","year":"2004","journal-title":"JACC"},{"issue":"1","key":"10.1002\/14651858.CD012721.pub3-BIB0531|cit531","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/HYPERTENSIONAHA.107.093682","article-title":"Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction","volume":"51","author":"Thune","year":"2008","journal-title":"Hypertension"},{"issue":"5","key":"10.1002\/14651858.CD012721.pub3-BIB0532|cit532","first-page":"494","article-title":"Heart failure with preserved systolic function","volume":"82","author":"Tinoco Mesquita","year":"2004","journal-title":"Arquivos Brasileiros de Cardiologia"},{"issue":"3","key":"10.1002\/14651858.CD012721.pub3-BIB0533|cit533","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/S0735-1097(00)00796-8","article-title":"Spironolactone inhibits the transcardiac extraction of aldosterone in patients with congestive heart failure","volume":"36","author":"Tsutamoto","year":"2000","journal-title":"JACC"},{"issue":"5","key":"10.1002\/14651858.CD012721.pub3-BIB0534|cit534","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0735-1097(01)01116-0","article-title":"Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure","volume":"37","author":"Tsutamoto","year":"2001","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0535|cit535","first-page":"323","article-title":"Left ventricular remodeling post myocardial infarction","volume":"63 Suppl 3","author":"Tsutamoto","year":"2005","journal-title":"Nippon Rinsho"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0536|cit536","first-page":"463","article-title":"Comparative efficacy of combined therapy with angiotensin converting enzyme inhibitor and angiotensin receptor blocker and direct renin inhibitor in patients with severe chronic heart failure","volume":"31","author":"Tumasyan","year":"2010","journal-title":"European Heart Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012721.pub3-BIB0537|cit537","first-page":"75","article-title":"Comparative efficacy of renin-angiotensin system modulators on prognosis, right and left heart functional parameters in chronic heart failure in relation to mid-ranged or preserved ejection fraction","volume":"20","author":"Tumasyan","year":"2018","journal-title":"European Journal of Heart Failure"},{"issue":"9","key":"10.1002\/14651858.CD012721.pub3-BIB0538|cit538","first-page":"1683","article-title":"Angiotensin receptor blockers in chronic heart failure","volume":"61","author":"Umemoto","year":"2003","journal-title":"Nippon Rinsho"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0539|cit539","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1038\/sj.jhh.1001094","article-title":"Vasoactive peptides and procollagen propeptides in patients with hypertension in relation to cardiac hypertrophy and diastolic heart failure: design of the study and patient characteristics","volume":"15 Suppl 1","author":"Uusimaa","year":"2001","journal-title":"Journal of Human Hypertension"},{"issue":"8861","key":"10.1002\/14651858.CD012721.pub3-BIB0540|cit540","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/0140-6736(93)90808-T","article-title":"Reversion of tachycardiomyopathy after beta-blocker","volume":"341","author":"Van den Berg","year":"1993","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD012721.pub3-BIB0541|cit541","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S1071-9164(05)80004-1","article-title":"Effects of lisinopril in patients with heart failure and chronic atrial fibrillation","volume":"1","author":"Van den Berg","year":"1995","journal-title":"Journal of Cardiac Failure"},{"issue":"1","key":"10.1002\/14651858.CD012721.pub3-BIB0542|cit542","first-page":"5","article-title":"The role of beta-blockers in the treatment of chronic cardiac failure","volume":"79","author":"Vasiuk","year":"2001","journal-title":"Klinicheskaia Meditsina"},{"issue":"19","key":"10.1002\/14651858.CD012721.pub3-BIB0543|cit543","first-page":"e745","article-title":"Changes in sodium and renal function may contribute to the beneficial effects of eplerenone on mortality and morbidity in the EPHESUS trial","volume":"125","author":"Vincent","year":"2012","journal-title":"Circulation"},{"issue":"2","key":"10.1002\/14651858.CD012721.pub3-BIB0544|cit544","first-page":"36","article-title":"Losartan in therapy of chronic heart failure","volume":"78","author":"Vizir","year":"2000","journal-title":"Klinicheskaia Meditsina"},{"issue":"9","key":"10.1002\/14651858.CD012721.pub3-BIB0545|cit545","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.amjcard.2010.06.052","article-title":"Effect of spironolactone on left ventricular ejection fraction and volumes in patients with class I or II heart failure","volume":"106","author":"Vizzardi","year":"2010","journal-title":"American Journal of Cardiology"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0546|cit546","first-page":"934","article-title":"The effect of aldosterone-antagonist therapy on aortic elastic properties in patients with moderate heart failure","volume":"33","author":"Vizzardi","year":"2012","journal-title":"European Heart Journal"},{"issue":"12","key":"10.1002\/14651858.CD012721.pub3-BIB0547|cit547","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1007\/s00392-015-0877-5","article-title":"Effects of spironolactone on ventricular-arterial coupling in patients with chronic systolic heart failure and mild symptoms","volume":"104","author":"Vizzardi","year":"2015","journal-title":"Clinical Research in Cardiology"},{"issue":"9","key":"10.1002\/14651858.CD012721.pub3-BIB0548|cit548","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2459\/JCM.0000000000000102","article-title":"The effect of aldosterone-antagonist therapy on aortic elastic properties in patients with nonischemic dilated cardiomyopathy","volume":"16","author":"Vizzardi","year":"2015","journal-title":"Journal of Cardiovascular Medicine"},{"issue":"6","key":"10.1002\/14651858.CD012721.pub3-BIB0549|cit549","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1161\/01.CIR.86.6.1800","article-title":"Angiotensin converting enzyme inhibition restores cardiac and hormonal responses to volume overload in patients with dilated cardiomyopathy and mild heart failure","volume":"86","author":"Volpe","year":"1992","journal-title":"Circulation"},{"issue":"9","key":"10.1002\/14651858.CD012721.pub3-BIB0550|cit550","first-page":"625","article-title":"The HEAAL study","volume":"11","author":"Volpe","year":"2010","journal-title":"Giornale Italiano di Cardiologia"},{"issue":"8","key":"10.1002\/14651858.CD012721.pub3-BIB0551|cit551","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1136\/hrt.2008.144816","article-title":"Treating diastolic heart failure","volume":"94","author":"Voors","year":"2008","journal-title":"Heart"},{"issue":"5","key":"10.1002\/14651858.CD012721.pub3-BIB0552|cit552","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S1388-9842(03)00105-3","article-title":"Increased exercise ejection fraction and reversed remodeling after long-term treatment with metoprolol in congestive heart failure: a randomized, stratified, double-blind, placebo-controlled trial in mild to moderate heart failure due to ischemic or idiopathic dilated cardiomyopathy","volume":"5","author":"Waagstein","year":"2003","journal-title":"European Journal of Heart Failure"},{"issue":"15","key":"10.1002\/14651858.CD012721.pub3-BIB0553|cit553","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0002-9149(99)80717-6","article-title":"Survival with oral d-sotalol in patients with left ventricular dysfunction after myocardial infarction: rationale, design, and methods (the SWORD trial)","volume":"75","author":"Waldo","year":"1995","journal-title":"American Journal of Cardiology"},{"issue":"9019","key":"10.1002\/14651858.CD012721.pub3-BIB0554|cit554","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(96)02149-6","article-title":"Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol.[Erratum appears in Lancet 1996 Aug 10;348(9024):416]","volume":"348","author":"Waldo","year":"1996","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD012721.pub3-BIB0555|cit555","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/S0735-1097(99)00048-0","article-title":"Losartan improves exercise tolerance in patients with diastolic dysfunction and a hypertensive response to exercise","volume":"33","author":"Metzger","year":"1999","journal-title":"JACC"},{"issue":"2","key":"10.1002\/14651858.CD012721.pub3-BIB0556|cit556","first-page":"81","article-title":"Management of hypertension and heart failure with AT1 receptor blockade","volume":"51","author":"Weinberg","year":"2001","journal-title":"JPMA"},{"issue":"9","key":"10.1002\/14651858.CD012721.pub3-BIB0557|cit557","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1161\/01.CIR.0000157146.86758.BC","article-title":"Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure","volume":"111","author":"Weintraub","year":"2005","journal-title":"Circulation"},{"issue":"12","key":"10.1002\/14651858.CD012721.pub3-BIB0558|cit558","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1093\/eurjhf\/hfr129","article-title":"Aldosterone and cortisol predict medium-term left ventricular remodelling following myocardial infarction","volume":"13","author":"Weir","year":"2011","journal-title":"European Journal of Heart Failure"},{"issue":"5","key":"10.1002\/14651858.CD012721.pub3-BIB0559|cit559","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S0735-1097(02)02063-6","article-title":"Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study","volume":"40","author":"Wong","year":"2002","journal-title":"JACC"},{"issue":"11","key":"10.1002\/14651858.CD012721.pub3-BIB0560|cit560","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/j.jacc.2003.12.053","article-title":"Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan heart failure trial (Val-HeFT) echocardiographic data","volume":"43","author":"Wong","year":"2004","journal-title":"JACC"},{"issue":"6","key":"10.1002\/14651858.CD012721.pub3-BIB0561|cit561","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1161\/01.CIR.84.6.2426","article-title":"Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy","volume":"84","author":"Woodley","year":"1991","journal-title":"Circulation"},{"issue":"12","key":"10.1002\/14651858.CD012721.pub3-BIB0562|cit562","doi-asserted-by":"crossref","first-page":"A1127","DOI":"10.1016\/S0735-1097(14)61127-X","article-title":"Use of plasma markers of fibrosis to predict responders to the use of spironolactone in stage b heart failure: A strain analysis","volume":"63","author":"Wright","year":"2014","journal-title":"JACC"},{"issue":"15","key":"10.1002\/14651858.CD012721.pub3-BIB0563|cit563","first-page":"2342","article-title":"Improving effect of carvedilol on cardiac function and exercise tolerance in patients with congestive heart failure of dilated cardiomyopathy","volume":"6","author":"Wu","year":"2002","journal-title":"Chinese Journal of Clinical Rehabilitation"},{"issue":"13","key":"10.1002\/14651858.CD012721.pub3-BIB0564|cit564","first-page":"2537","article-title":"Effect of carvedilol on left ventricular function of patients with congestive heart failure evaluated by Doppler image","volume":"11","author":"Xu","year":"2007","journal-title":"Journal of Clinical Rehabilitative Tissue Engineering Research"},{"issue":"2","key":"10.1002\/14651858.CD012721.pub3-BIB0565|cit565","first-page":"262","article-title":"Aldosterone antagonist therapy for chronic heart failure","volume":"94","author":"Yamamoto","year":"2005","journal-title":"Nippon Naika Gakkai Zasshi"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0566|cit566","first-page":"E262","article-title":"Effects of benazepril on left ventricular remodelling and exercise tolerance in patients with valvular heart failure","volume":"98","author":"Yan","year":"2012","journal-title":"Heart"},{"issue":"21","key":"10.1002\/14651858.CD012721.pub3-BIB0567|cit567","first-page":"A8406","article-title":"The addition of direct renin inhibitor aliskiren to standard therapy suppresses enhanced cardiac sympathetic activity in patients with systolic heart failure","volume":"124","author":"Yoshihiro","year":"2011","journal-title":"Circulation"},{"issue":"17","key":"10.1002\/14651858.CD012721.pub3-BIB0568|cit568","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1161\/01.CIR.0000146819.43235.A9","article-title":"Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials","volume":"110","author":"Young","year":"2004","journal-title":"Circulation"},{"issue":"4","key":"10.1002\/14651858.CD012721.pub3-BIB0569|cit569","first-page":"294","article-title":"Effectiveness of losartan and benazepril in improving diastolic function of left ventricle in patients with heart failure and hypertension","volume":"6","author":"Zeng","year":"2006","journal-title":"Pharmaceutical Care and Research"},{"issue":"6","key":"10.1002\/14651858.CD012721.pub3-BIB0570|cit570","first-page":"1111","article-title":"Effect of carvedilol on heart function and glucolipometabolic in elder patients with diastolic heart failure","volume":"35","author":"Zheng","year":"2009","journal-title":"Journal of Jilin University (Medicine Edition)"},{"issue":"44","key":"10.1002\/14651858.CD012721.pub3-BIB0571|cit571","first-page":"42","article-title":"Selective aldosterone blocking in heart failure. Eplerenone reduces the risk after infarction","volume":"145","year":"2003","journal-title":"MMW Fortschritte der Medizin"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0572|cit572","first-page":"S108","article-title":"Assessment of the Quality of Life (SF36) after optimized cardiovascular therapy in Chagas cardiomyopathy","volume":"9","author":"Botoni","year":"2010","journal-title":"European Journal of Heart Failure Supplement"},{"issue":"3","key":"10.1002\/14651858.CD012721.pub3-BIB0573|cit573","first-page":"3","article-title":"The effect of aldosterone receptor blockade in diastolic heart failure in patients with arterial hypertension combined with chronic obstructive pulmonary disease","volume":"17","author":"Dielievska","year":"2015","journal-title":"General Medicine"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0574|cit574","unstructured":"Effects of candesartan cilexetil vs standard therapy on serum levels of brain natriuretic peptide in patients suffering from chronic heart failure with depressed and preserved systolic function www.clinicaltrialsregister.eu\/ctr-search\/trial\/2005-001306-87\/IT#P"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0575|cit575","unstructured":"Comparative effects of telmisartan and candesartan on glucose metabolism in patients with chronic heart failure www.clinicaltrialsregister.eu\/ctr-search\/trial\/2005-002109-22\/AT"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012721.pub3-BIB0576|cit576","first-page":"53","article-title":"ACE-inhibitors, AT1 receptor antagonists and diastolic dysfunction","volume":"44","author":"Metra","year":"1999","journal-title":"Cardiologia"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0577|cit577","unstructured":"A multicenter, randomized, double blind, parallel group, active controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients (NYHA class II-IV) with preserved ejection fraction www.ins.gob.pe\/ensayosclinicos\/rpec\/recuperarECPBNuevo.asp?ver=EN&numEc=010-15"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD012721.pub3-BIB0578|cit578","first-page":"iii223","article-title":"Effect of aldosterone antagonism on active and passive determinants of LV diastolic filling and exercise intolerance in heart faillure with preserved ejection fraction","volume":"18","author":"Przewlocka-Kosmala","year":"2017","journal-title":"European Heart Journal Supplements"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012721.pub3-BIB0579|cit579","first-page":"61","article-title":"Beta blockers and calcium antagonists in diastolic dysfunction","volume":"44","author":"Rapezzi","year":"1999","journal-title":"Cardiologia"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0580|cit580","unstructured":"Aldosterone antagonist delays the progression of diastolic dysfunction in patients with hypertension and myocardial hypertrophy: a randomised controlled clinical trial www.chictr.org.cn\/showprojen.aspx?proj=16311"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0581|cit581","unstructured":"Treatment of diastolic heart failure: the role of blockade of the renin-angiotensin system. A comparison of diuretics with an angiotensin converting enzyme inhibitor, angiotensin receptor blockade or diuretics alone www.chictr.org.cn\/showprojen.aspx?proj=8904"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0582|cit582","unstructured":"Evaluation of efficacy and safety of metoprolol in patients having heart failure with normal ejection fraction: a randomised, double-blind, placebo-controlled trial www.ctri.nic.in\/Clinicaltrials\/pdf_generate.php?trialid=1626&EncHid=&modid=&compid=%27,%271626det%27"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0583|cit583","unstructured":"A 24-week, randomized, double-blind, multi-center, parallel group, active controlled study to evaluate the effect of LCZ696 on NT-proBNP, symptoms, exercise function and safety compared to individualized medical management of comorbidities in patients with heart failure and preserved ejection fraction www.ctri.nic.in\/Clinicaltrials\/pdf_generate.php?trialid=19155&EncHid=&modid=&compid=%27,%2719155det%27"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0584|cit584","unstructured":"A multicenter, randomized, double-blind, active-controlled study to evaluate the effects of LCZ696 compared to valsartan on cognitive function in patients with chronic heart failure and preserved ejection fraction (PERSPECTIVE) www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-001254-17\/GB"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0585|cit585","unstructured":"A 24-week, randomized, double-blind, multi-center, parallel group, active controlled study to evaluate the effect of LCZ696 on NT-proBNP, exercisecapacity, symptoms and safety compared to individualized medical management of comorbidities in patients with heart failure and preserved ejection fraction www.clinicaltrialsregister.eu\/ctr-search\/search?query=2016-003410-28"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0586|cit586","unstructured":"Spironolactone In the treatment of heart failure: a double-blind, randomized, placebo-controlled, parallel group, interventional phase III study to evaluate the efficacy and safety of spironolactone compared to placebo on the composite endpoint of recurrent heart failure hospitalizations and cardiovascular death in patients with heart failure with mid- range or preserved ejection fraction (SPIRIT-HF) www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-000697-11\/DE"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0587|cit587","unstructured":"Spironolactone initiation registry randomized interventional trial in heart failure with preserved ejection fraction (SPIRRIT) clinicaltrials.gov\/show\/NCT02901184"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0588|cit588","unstructured":"LCZ696 in advanced LV hypertrophy and HFpEF clinicaltrials.gov\/ct2\/show\/NCT03928158"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0589|cit589","unstructured":"Carvedilol SR study for biomarkers from blood and urine and safety of in patients with heart failure with preserved ejection fraction clinicaltrials.gov\/ct2\/show\/NCT03948685"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0590|cit590","unstructured":"Changes in NT-proBNP and outcomes, safety, and tolerability in HFpEF patients with acute decompensated heart failure (ADHF) who have been stabilized during hospitalization and initiated in-hospital or within 30 days post-discharge (PARAGLIDE-HF) clinicaltrials.gov\/ct2\/show\/NCT03988634"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0591|cit591","unstructured":"Study of sacubitril\/valsartan on myocardIal oxygenation and fibrosis in heart failure with preserved ejection fraction (PRISTINE-HF) clinicaltrials.gov\/ct2\/show\/NCT04128891"},{"issue":"2","key":"10.1002\/14651858.CD012721.pub3-BIB0592|cit592","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/eurjhf\/hfp193","article-title":"Rationale and design of the beta-blocker in heart failure with normal left ventricular ejection fraction (beta-PRESERVE) study","volume":"12","author":"Zhou","year":"2010","journal-title":"European Journal of Heart Failure"},{"issue":"9146","key":"10.1002\/14651858.CD012721.pub3-BIB0593|cit593","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial","volume":"353","author":"II","year":"1999","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD012721.pub3-BIB0594|cit594","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/eurheartj\/ehx564","article-title":"Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials","volume":"39","author":"Cleland","year":"2018","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0595|cit595","volume-title":"Statistical Power Analysis in the Behavioral Sciences","author":"Cohen","year":"1988"},{"issue":"23","key":"10.1002\/14651858.CD012721.pub3-BIB0596|cit596","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","author":"Group CONSENSUS Trial Study","year":"1987","journal-title":"New England Journal of Medicine"},{"issue":"17","key":"10.1002\/14651858.CD012721.pub3-BIB0597|cit597","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1056\/NEJMc1612601","article-title":"Spironolactone metabolites in TOPCAT - new insights into regional variation","volume":"376","author":"Denus","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0598|cit598","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Deeks","year":"2011"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0599|cit599","doi-asserted-by":"crossref","unstructured":"Deeks JJ Higgins JP Chapter 10: analysing data and undertaking meta-analyses Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019) Cochrane","DOI":"10.1002\/9781119536604"},{"issue":"1","key":"10.1002\/14651858.CD012721.pub3-BIB0600|cit600","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.amjcard.2015.03.052","article-title":"Meta-analysis of large-scale randomized trials to determine the effectiveness of inhibition of the renin-angiotensin aldosterone system in heart failure","volume":"116","author":"Emdin","year":"2015","journal-title":"American Journal of Cardiology"},{"issue":"3","key":"10.1002\/14651858.CD012721.pub3-BIB0601|cit601","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","article-title":"Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)","volume":"26","author":"Flather","year":"2005","journal-title":"European Heart Journal"},{"issue":"6","key":"10.1002\/14651858.CD012721.pub3-BIB0602|cit602","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/jamainternmed.2015.0924","article-title":"A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010","volume":"175","author":"Weston Susan","year":"2015","journal-title":"JAMA Internal Medicine"},{"issue":"38","key":"10.1002\/14651858.CD012721.pub3-BIB0603|cit603","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonzalez-Lopez","year":"2015","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0604|cit604","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2015"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0605|cit605","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]","author":"Higgins","year":"2011"},{"issue":"10","key":"10.1002\/14651858.CD012721.pub3-BIB0606|cit606","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1001\/jama.283.10.1295","article-title":"Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR\/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group","volume":"283","author":"Hjalmarson","year":"2000","journal-title":"JAMA"},{"issue":"6","key":"10.1002\/14651858.CD012721.pub3-BIB0607|cit607","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.pcad.2005.02.001","article-title":"Neurohumoral pathways in heart failure with preserved systolic function","volume":"47","author":"Hogg","year":"2005","journal-title":"Progress in Cardiovascular Diseases"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0608|cit608","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/ehf2.12204","article-title":"Renin-angiotensin blockade in heart failure with preserved ejection fraction: a systematic review and meta-analysis","volume":"4","author":"Khan","year":"2017","journal-title":"ESC Heart Failure"},{"issue":"9961","key":"10.1002\/14651858.CD012721.pub3-BIB0609|cit609","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1016\/S0140-6736(14)61373-8","article-title":"Efficacy of \u03b2 blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis","volume":"384","author":"Kotecha","year":"2014","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0610|cit610","doi-asserted-by":"crossref","unstructured":"Lefebvre C Glanville J Briscoe S Littlewood A Marshall C Noel-Storr A Chapter 4: Searching for and selecting studies Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Welch VA Cochrane Handbook for Systematic Reviews of Interventions. Version 6.0 (updated July 2019) Cochrane","DOI":"10.1002\/9781119536604.ch4"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0611|cit611","first-page":"35","article-title":"Effects of spironolactone in heart failure with preserve ejection fraction: a meta-analysis of randomized controlled trials","volume":"97","author":"Li","year":"2018","journal-title":"Medicine"},{"issue":"11","key":"10.1002\/14651858.CD012721.pub3-BIB0612|cit612","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013Neprilysin Inhibition versus Enalapril in Heart Failure","volume":"371","author":"McMurray","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"9169","key":"10.1002\/14651858.CD012721.pub3-BIB0613|cit613","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Effect of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0614|cit614","unstructured":"Chronic heart failure in adults: diagnosis and management www.nice.org.uk\/guidance\/ng106"},{"issue":"23","key":"10.1002\/14651858.CD012721.pub3-BIB0615|cit615","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1161\/01.CIR.100.23.2312","article-title":"Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group","volume":"100","author":"Packer","year":"1999","journal-title":"Circulation"},{"issue":"22","key":"10.1002\/14651858.CD012721.pub3-BIB0616|cit616","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJM200105313442201","article-title":"Effect of carvedilol on survival in severe chronic heart failure","volume":"344","author":"Packer","year":"2001","journal-title":"New England Journal of Medicine"},{"issue":"17","key":"10.1002\/14651858.CD012721.pub3-BIB0617|cit617","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1161\/01.CIR.0000035653.72855.BF","article-title":"Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"issue":"1","key":"10.1002\/14651858.CD012721.pub3-BIB0618|cit618","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the Treatment of Preserved Cardiac FunctionHeart Failure With an Aldosterone Antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"issue":"10","key":"10.1002\/14651858.CD012721.pub3-BIB0619|cit619","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure","volume":"341","author":"Remme Willem","year":"1999","journal-title":"New England Journal of Medicine"},{"issue":"15","key":"10.1002\/14651858.CD012721.pub3-BIB0620|cit620","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"27","key":"10.1002\/14651858.CD012721.pub3-BIB0621|cit621","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"European Heart Journal"},{"issue":"3","key":"10.1002\/14651858.CD012721.pub3-BIB0622|cit622","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/1071-9164(95)90025-X","article-title":"Use of the Living With Heart Failure questionnaire to ascertain patients' perspectives on improvement in quality of life versus risk of drug-induced death","volume":"1","author":"Rector T","year":"1995","journal-title":"Journal of Cardiac Failure"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0623|cit623","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2014"},{"issue":"6","key":"10.1002\/14651858.CD012721.pub3-BIB0624|cit624","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1161\/CIRCRESAHA.113.300268","article-title":"Epidemiology of heart failure","volume":"113","author":"Roger","year":"2013","journal-title":"Circulation Research"},{"issue":"1","key":"10.1002\/14651858.CD012721.pub3-BIB0625|cit625","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/ejhf.29","article-title":"Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved","volume":"16","author":"Rogers","year":"2014","journal-title":"European Journal of Heart Failure"},{"issue":"18","key":"10.1002\/14651858.CD012721.pub3-BIB0626|cit626","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1001\/jama.1995.03530180056031","article-title":"Rationale for treatment of patients with chronic heart failure with adrenergic blockade","volume":"274","author":"Sackner-Bernstein","year":"1995","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0627|cit627","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1161\/CIRCRESAHA.115.302922","article-title":"Heart failure with preserved ejection fraction mechanisms, clinical features, and therapies","volume":"115","author":"Sharma","year":"2014","journal-title":"Circulation Research"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0628|cit628","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 inheart failure with preserved ejection fraction: a phase 2double-blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD012721.pub3-BIB0629|cit629","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/eurheartj\/ehv464","article-title":"Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction","volume":"37","author":"Solomon Scott","year":"2016","journal-title":"European Heart Journal"},{"issue":"5","key":"10.1002\/14651858.CD012721.pub3-BIB0630|cit630","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.119.044586","article-title":"Sacubitril\/Valsartan across the spectrum of ejection fraction in heart failure","volume":"141","author":"Solomon","year":"2020","journal-title":"Circulation"},{"issue":"5","key":"10.1002\/14651858.CD012721.pub3-BIB0631|cit631","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"Yusuf","year":"1991","journal-title":"New England Journal of Medicine"},{"issue":"327","key":"10.1002\/14651858.CD012721.pub3-BIB0632|cit632","first-page":"685","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions","volume":"1992","author":"SOLVD Investigators","year":"1992","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0633|cit633","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.ahj.2004.12.010","article-title":"Cardiovascular Outcomes Research Consortium. Monitoring clinical changes in patients with heart failure: a comparison of methods","volume":"150","author":"Spertus","year":"2005","journal-title":"American Heart Journal"},{"issue":"2","key":"10.1002\/14651858.CD012721.pub3-BIB0634|cit634","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/eurjhf\/hfr170","article-title":"Ten-year prognosis of heart failure in the community: follow-up data from the Echocardiographic Heart of England Screening (ECHOES) study","volume":"14","author":"Taylor","year":"2012","journal-title":"European Journal of Heart Failure"},{"issue":"1","key":"10.1002\/14651858.CD012721.pub3-BIB0635|cit635","first-page":"41","article-title":"Developing optimal search strategies for detecting clinically sound treatment studies in EMBASE","volume":"94","author":"Wong","year":"2006","journal-title":"Journal of the Medical Library Association"},{"issue":"16","key":"10.1002\/14651858.CD012721.pub3-BIB0636|cit636","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"Journal of the American College of Cardioliology"},{"issue":"6","key":"10.1002\/14651858.CD012721.pub3-BIB0637|cit637","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","article-title":"2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"},{"issue":"9386","key":"10.1002\/14651858.CD012721.pub3-BIB0638|cit638","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD012721.pub3-BIB0639|cit639","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012721.pub3-BIB0640|cit640","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1136\/heartjnl-2017-311652","article-title":"Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis","volume":"104","author":"Zheng","year":"2018","journal-title":"Heart"},{"issue":"7","key":"10.1002\/14651858.CD012721.pub3-BIB0641|cit641","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012721","article-title":"Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction","author":"Lumbers","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD012721.pub3-BIB0642|cit642","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012721.pub2","article-title":"Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction","author":"Martin","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T15:05:44Z","timestamp":1761231944000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012721.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Heart Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,5,22]]},"references-count":642,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,5]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012721.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,22]]}}}